Therapeutic Vascular and Immune Normalization in the Melanoma Microenvironment Using STING Agonists by Chelvanambi, Manoj
  
Title Page 
Therapeutic Vascular and Immune Normalization in the Melanoma Microenvironment 























Submitted to the Graduate Faculty of the 
 
School of Medicine in partial fulfillment 
  
of the requirements for the degree of 
 














Committee Membership Page 
UNIVERSITY OF PITTSBURGH 
 


















It was defended on 
 
March 12, 2021 
 
and approved by 
 
Robert J. Binder, Ph.D., Professor, Department of Immunology, University of Pittsburgh 
 
Lisa H. Butterfield, Ph.D., Adjunct Professor, Department of Microbiology and Immunology, 
University of California, San Francisco 
 
Louis D. Falo Jr., M.D., Ph.D., Professor, Department of Dermatology, University of Pittsburgh 
Simon C. Watkins, Ph.D., Professor, Department of Cellular Biology, University of Pittsburgh 
Dissertation Director: Walter J. Storkus, Ph.D., Professor, Department of Dermatology, 


































Therapeutic Vascular and Immune Normalization in the Melanoma Microenvironment 




Manoj Chelvanambi, PhD 
 





CD8+ T-cells are indispensable for immune-mediated rejection of solid cancers. Hence, the 
conditional enhancement of intratumoral T-cell content and/or function defines a preferred 
outcome for successful immunotherapies. Activated anti-tumor CD8+ T-cells rely on functional 
blood vessels for their efficient trafficking to, and extravasation into, the tumor parenchyma. 
Indeed, pathologic progression of solid tumors is closely associated with the development of 
structurally and functionally abnormal tumor blood vessels which impede T-cell infiltration into 
cancer lesions. In this regard, therapeutic dosing of anti-angiogenic interventional strategies 
fortifies or reprograms tumor blood vessels (or vascular normalization) to significantly improve 
intratumoral CD8+ T-cell infiltration. Intriguingly, agonists of Stimulator of Interferon Genes 
(STING), which evolved from a class of anti-angiogenic agents, have recently demonstrated 
significant clinical promise for their ability to enhance CD8+ T-cell recruitment into tumors but 
whether therapeutic changes to the tumor vasculature underlies successful immune-mediated 
tumor control remain only partially resolved. Indeed, in this thesis, I demonstrate that intratumoral 
administration of STING agonist ADU S-100 induces vascular normalization (i.e., improved 
vascular perfusion, enhanced pericyte coverage and increased endothelial activation) and enhances 
tumor infiltration by immune cells, specifically, CD8+ T-cells and CD11c+ dendritic cells (DC). 
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STING activation also increases local production of pro-inflammatory cytokines/chemokines that 
sponsor the development of high endothelial venules (HEV) and HEV-associated tertiary 
lymphoid structures (TLS) within the therapeutic melanoma tumor microenvironment (TME). 
HEV/TLS formation with STING agonism was further linked to evidence of local T-cell cross-
priming by tumor-resident antigen presenting cells (APC) within the tumor microenvironment 
(TME), with the therapeutic tumor infiltrating lymphocyte (TIL) repertoire exhibiting enrichment 
in T cell clonotypes found in the periphery as well as those detected only within the TME. These 
vasculature-centric underpinnings for the efficacy of STING agonist-based interventions provide 
enthusiasm for improved translational value of future combinational cancer immunotherapies that 
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1.1 Epidemiology of melanoma 
With an incidence of ~1,000,000 new cases every year, skin cancer is the most common solid 
malignancy in the western hemisphere and accounts for roughly one-third of all cancer diagnoses 
in the United States 1.  Skin cancer can be broadly categorized into non-melanoma skin cancer 
(NMSC) and malignant melanoma (MM) which impact different cell types in the skin 2. 
MM affects the pigment producing melanocytes residing at the interface of the epidermal-
dermal junctional layer of the skin. It is the rarest amongst all forms of skin cancer with an 
incidence of ~160,000 new cases every year, with primary risk factors for MM including age, 
degree of UV exposure and the sex of a patient 3-5. Despite a low rate of incidence compared to 
other forms of solid cancer, MM is a major health concern due to its aggressive nature, which gives 
rise to metastatic lesions in distal (and frequently surgically inaccessible) anatomic sites. MM 
incidence rates have sharply increased over the past few decades, with now roughly 1 in 50 
Caucasian adults at significant risk of developing cutaneous malignant melanoma 6 7. Incidence 
rates for MM also increase with age 8. The following sections detail the most common risk factors 
for developing metastatic melanoma. 
1.1.1 Risk factors  
1.1.1.1 Extrinsic risk factor: ultraviolet radiation 
UV radiation comprises low-wavelength, high-energy emissions from the sun which readily 
penetrate human skin. Short periods of exposure to solar UV radiation improves dermal 
biosynthesis of vitamin D necessary for physiological well-being and the production of eumelanin 
by melanocytes through the MSH-MC1R signaling axis, which serves to acutely shield the skin 
2 
 
from UV 9 10. However, prolonged UV exposure can have deleterious genotoxic effects in exposed 
skin cells in support of neoplastic transformation, thus making UV a potent carcinogen at high 
exposures 10. Consequently, keratinocytes and melanocytes have evolved to respond to genotoxic 
UV exposure by changing their cellular and physiological properties to limit further cellular/tissue 
damage.  
Keratinocytes demonstrate a remarkably low tolerance for UV radiation and undergo rapid 
DNA repair and/or apoptosis upon chronic UV exposure. During this repair process, keratinocytes 
promote melanocytic production of eumelanin (black or brown pigment) which they readily 
internalize to shield against UV-induced genotoxicity 10. In the absence of such keratinocyte-
melanocyte interactions, melanocytes primarily produce pheomelanin (red pigment) which when 
found in large quantities may independently drive melanomagenesis by inducing ROS-dependent 
DNA damage in melanocytes 11 12. 
On the other hand, melanocytes demonstrate a distinct ability to withstand extreme doses of 
UV radiation, but respond uniquely by accumulating C -> T transitional mutations, which 
promotes rapid cell proliferation 10 13 14. This specialized resistance of melanocytes to UV exposure 
underlies the large mutational burden observed in clinical specimens of cutaneous malignant 
melanoma (CMM), where driver mutations in RAC1, STK19 and PPP6C in human CMM have 
been linked to UV-induced C->T transitional mutations 15. Additionally, UV-A/B radiation also 
promotes melanocytic proliferation by accelerating cell-cycle signaling and by amplifying JNK 
signaling cascades 16 17.  
Thus, exposure to UV radiation is considered a key melanoma risk factor due to its ability to 
initiate and drive oncogenic pathways in several skin-resident cell types. 
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1.1.1.2 Host risk factors 
1.1.1.2.1 Nevi 
A melanocytic nevus is a benign neoplasia consisting of melanocytes and nevus cells that 
together produce melanin in localized lesions 4. While benign nevi appear early in the first two 
decades of life and stabilize or regress with age, cancerous melanocytic nevi appear later in life 
(after 40 years of age) and increase in prevalence with advanced age 18-21. Cancerous nevi are 
typically 2-5 mm in diameter and fall into one of three categories depending on the location of the 
melanocytic nests within the skin: junctional nevi, intradermal nevi and compound nevi 22. 
Regardless of their type, the presence of nevi predisposes a patient to higher melanoma risk by 
serving as hotbeds for melanocytic maturation and proliferation 22. Mutations in candidate genes 
within the RAS, RAF and MEK/ERK family (Nras, Braf, Craf, MAPK etc.,) are strongly linked 
to the development of cancerous nevi and indeed play a major role in cancer progression beyond 
nevus formation 22-24.  
In this regard, ~25%-33% of melanoma lesions observed in patients evolve from pre-existing 
melanocytic nevi 19, with incidence increasing to ~50% in patients with high nevus counts (>100) 
21. Therefore, genetic, histologic, and pathologic evidence suggests that, when present, nevi 
represent a significant risk factor for the development of melanoma.  
1.1.1.2.2 Genetic mutations 
1.1.1.2.2.1 CDKN2A 
Cell cycle progression determines the kinetics and frequency of cell division and is therefore a 
strictly regulated process in normal non-malignant cells. Several germ-line encoded proteins such 
as cyclins, cyclin-dependent kinases and inhibitors of cyclin-dependent kinases orchestrate cell 
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proliferation and represent hotspots for mutagenesis in pre-malignant cells 25. Indeed, mutations 
in one such cell cycle gene, Cdkn2a, have been found to be associated with ~20% of families with 
a history of melanoma 26. 
Cdkn2a is a germ-line encoded tumor suppressor gene that is subject to alternative splicing to 
produce two tumor suppressor proteins; CDKN2A (p16INK4A) encoded by the alpha-variant and 
p14ARF encoded by the beta-variant 27 28. CDKN2A functions as an inhibitor of cell cycle 
progression by regulating CDK4/6-mediated activation of the retinoblastoma (Rb)-E2F axis by 
p16INK4A and by activating the tumor suppressor p53 via p14ARF 28. Accordingly, missense 
and/or nonsense germline mutations in CDKN2A disrupt cell cycle progression and promote 
tumorigenesis. Specifically, p16INK4A mutations negatively affect binding and inhibition of 
CDK4/6, which leads to hyperphosphorylation of Rb and a loss of sequestration of the transcription 
factor E2F, which ultimately promotes G1-S transition in tumor cells 29 30. Additionally, p14 
mutations prevent its antagonism of the p53-specific ubiquitin ligase, HDM2 which leads to the 
rapid degradation of the tumor suppressor p53 and the corresponding loss of G2 checkpoints 31.  
1.1.1.2.2.2 BRAF 
BRAF is an intermediary kinase within the MAPK (MEK-ERK) signaling cascade that initiates 
cellular proliferation in response to RAS activating growth factors. BRAF contains three functional 
domains, namely CR1-3, where CR1 (aa 120-280) detects activated RAS, CR3 activates the BRAF 
kinase (aa 457-717) while CR2 serves as a hinge between the two functional domains 32. In 
addition to detecting RAS activation, CR1 also functions as an autoinhibitory domain for CR3 to 
prevent aberrant activation of the MAPK cascade 32.  
Since BRAF functions as an amplifier of RAS dependent cell proliferation, mutations in any of 
the domains may acquire driver function in melanomagenesis. Indeed, BRAF is commonly 
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mutated in melanoma where ~60% of lesions harbor at least one of ~200 different mutations 
annotated 33. Specifically, class I BRAF mutations allow monomeric BRAF to activate MAPK 
signals independently from RAS activation and therefore function as the most potent oncogenic 
mutations. Expectedly, ~80% of all malignant melanoma lesions harbor the class I BRAF V600E 
mutation 33. BRAF may also drive melanomagenesis through fusion events where BRAF C-
terminal kinase domains couple with N-terminal domains from other oncogenes such as SOX10, 
AGK and SEPT3 to further promote MAPK signals 32.  
1.1.1.2.2.3 PTEN 
PTEN is a tumor suppressor gene with functional lipid phosphatase and protein phosphatase 
activity. PTEN reduces intracellular PIP3 levels through its lipid phosphatase activity and 
downregulates Akt/MAPK signaling to limit G1/S transition of the cell cycle 34. When active, 
PTEN also modulates apoptosis by upregulating pro-apoptotic protein BID and downregulating 
anti-apoptotic Bcl2 to conditionally select against pre-malignant cells 34. Consequently, loss-of-
function PTEN mutations could lead to tumorigenesis, and these are indeed frequently observed 
in melanoma patients 34. Given their functional convergence at the level of Akt/MAPK, concurrent 
gain of function BRAF mutations with loss of function PTEN mutations occur in ~20% of patients 
with malignant melanoma 35. 
1.1.2 Types of Melanoma 
1.1.2.1 Superficial Spreading Melanoma (SSM) 
SSM is the most common form of melanoma accounting for ~70% of all clinically diagnosed 
cases and is primarily found in intermittently exposed surfaces of skin i.e., on the backs of men 
and on the legs of women. Sharply outlined SSM lesions acquire a range of colors from black to 
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bluish hues and typically appear darker than surrounding normal tissue. SSM lesions are also 
palpable and develop into nodules that protrude several millimeters above the surface of the skin 
8 36 37.  
1.1.2.2 Nodular Melanoma (NM) 
NM accounts for ~5% of all melanoma cases and is also associated with intermittent exposure 
to sun. NM lesions appears in the trunk region and limbs and demonstrate an increased incidence 
in older males aged between 50-70 years. NM is characterized by a nodular growth pattern wherein 
nests of melanocytes grow in individual nodules before combining into a larger palpable nodule 
that often ulcerates. Further, dermal invasion is common with NM and often precedes metastatic 
growth 8 36 37.  
1.1.2.3 Lentigo Maligna Melanoma (LMM) 
LMM accounts for 4-15% of melanoma cases diagnosed and it primarily appears in dermal 
regions chronically exposed to sun and UV, such as the head and neck region. LMM is 
characterized by the proliferation of basal melanocytes and appears as a relatively flat lesion on 
the skin with only rare protruding growth 8 36 37.  
1.1.2.4 Acral Lentiginous Melanoma (ALM) 
ALM accounts for ~5% of melanoma cases and primarily localizes to skin of the extremities 
and digits such as in the palmoplantar and subungual regions. It occurs more commonly in non-
Caucasian populations with a selectively higher incidence in older females in Asian, African 
American and Hispanic populations 8 36 37. 
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1.1.2.5 Desmoplastic Melanoma (DM) 
DM accounts for ~2% of melanoma cases and results from chronic exposure to UV radiation 
and is most found in the head and neck region. DM incidence increases with age and is most 
commonly found in males > 60 years of age. DM lesions appear flush and are characterized by 
S100+ melanocytic composition and infiltration into perineural spaces within the skin 8 36 37.  
Other rare forms such as balloon cell melanoma, myxoid melanoma, osteogenic melanoma and 
rhabdoid melanoma are only rarely diagnosed 8. 
1.2 Current treatment options for patients with melanoma  
Melanoma poses a significant treatment challenge given its aggressive nature and high 
metastatic potential. While early lesions may be successfully resected via simple surgery, 
treatment of late-stage metastatic disease requires the use of noninvasive systemic drugs that are 
designed to access disseminated, and frequently, surgically inaccessible lesions 38. In this regard, 
therapeutic regimens employing neoadjuvant approaches have recently shown great promise. The 
following section highlights several preferred systemic treatment options for patients with 
melanoma. 
1.2.1 Chemotherapy 
1.2.1.1 Dacarbazine  
Dacarbazine/DTIC/DTIC-Dome is a DNA alkylating agent that transfers methyl groups to 
guanosine bases of cellular DNA 39. By inducing extensive DNA methylation, DTIC alters the 
spatial configuration of the DNA helix and makes genomic DNA less conducive to DNA 
replication, ultimately leading to cellular apoptosis 40-42. Therefore, DTIC serves as a cytostatic 
and cytotoxic drug used in the control of cancer. While all nucleated cells are susceptible to DTIC, 
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cancer cells predictably demonstrate a heightened sensitivity due to their increased proliferative 
capacity. However, despite its great promise, one major limitation of DTIC-based therapy lies in 
its lack of tumor targeting potential which often gives rise to severe (off target) adverse events 
(AE) in patients receiving treatment 43. While one class of AEs with DTIC leads to excessive 
gastrointestinal irritation, another class directly affects the immune system and leads to the onset 
of refractory cytopenia, lymphocytic anemia and neutropenia 43. However, since being approved 
for clinical use by the FDA in 1975, and despite only demonstrating nominal objective response 
rates (15.3% with 11.2% partial response (PR) and 4.2% complete response (CR); RECIST) 38 44 , 
DTIC is a key chemotherapeutic agent for patients with melanoma. More recently, DTIC has been 
evaluated in combination regimens such as in the ‘Dartmouth regimen’ (Cisplatin, Dacarbazine, 
Tamoxifen and Carmustine), with these complex regimens demonstrating promising yet only 
modest improvements in tumor response rate (proportion of CR or PR; RECIST) over DTIC 
monotherapy (18.5% in the Dartmouth regimen arm vs 10.2% in the Dacarbazine arm) 45 46. 
Furthermore, Temozolomide (MTIC, TMZ), an oral pro-drug version of the active metabolite of 
DTIC has also been tested in single-agent or combination regimens, however, these approaches 
provide no significant benefit over that provided by treatment with DTIC alone (median survival 
time of 7.7 months in the TMZ monotherapy arm vs 6.4 months in the DTIC monotherapy arm) 47 
48. Hence, while DTIC remains the chemotherapeutic drug of choice in the melanoma setting, 
modest clinical responses and the likelihood of severe AEs on-therapy highlights the need to 
develop newer and better tolerated chemical agents. 
Overall, chemotherapies remain attractive since they are comparatively inexpensive, effectively 
scalable, and easily stored and distributed. However, tumors notoriously develop resistance 
mechanisms to limit the access and persistence of such chemotherapeutic agents in the TME. 
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Notably, melanoma develops multidrug resistance (MDR), which through a variety of mechanisms 
49, enables rapid efflux and clearance of agents such as DTIC from tumor cells 50 51.  MDR, together 
with the selective pressure imposed by chemotherapies such as DTIC, therefore also favors the 
selection of stressor resistant tumor cells requiring the development and implementation of 
effective salvage therapies. 
1.2.2 Immunotherapy 
1.2.2.1 Cytokine therapy 
Interferons are a class of cytokines that orchestrate protective immune responses under 
conditions of physiological stress. Type I interferons (includes IFNα and IFNβ), are produced 
when innate pattern recognition receptors (PRR) are activated in stressed cells, where they mediate 
pro-inflammatory autocrine 52, paracrine and endocrine 53 cell/tissue defense mechanisms 54. In 
cancer, interstitial DNA or ctDNA from dead or dying tumor cells may also activate innate PRRs 
such as DNA-dependent activator of IRFs (DAI) 55, STING 56 57 and toll-like receptors (TLR) 58 
to induce strong local production of IFN-I in association with enhanced intratumoral infiltration 
of diverse anti-tumor immune cells 55 and the processing of tumor antigens by CD8a+ cross-
presenting DCs 59. 
Studies have shown that within the TME, DCs represent an indispensable source of IFN-I 
required for rejection of murine tumors, with therapy benefits linked to the direct activation of 
immune cells 55 and the upregulation of MHC-I antigen-presentation machinery in tumor cells for 
improved T-cell mediated immunosurveillance of cancer 60. These pleiotropic benefits have 
justified the use of IFN-I as a neoadjuvant in the treatment of melanoma, and since its approval for 
clinical use in 1995, i.v. treatment with bolus high-dose interferon alpha 2b for advanced stage 
melanoma has demonstrated promising response rates in multiple clinical trials (ORR ~22%) 61. 
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More recently, rhIFN- administered in a pegylated form (Peg-IFN-α-2b) has demonstrated 
enhanced tolerability and retention in patients 62. However, IFNα2b and Peg-IFN treatment often 
leads to immune-related adverse events (irAEs) including fever, chills, nausea, autoimmune 
conditions and ulceration of primary cutaneous lesions which negatively impact quality of life in 
patients on-treatment 38. Nevertheless, the robust inflammation achieved with IFN-I-based therapy 
still makes it an attractive adjuvant therapy component despite significant irAEs observed on-
treatment. 
1.2.2.2 Cellular therapy 
1.2.2.2.1 DC Vaccines 
DCs are found in high numbers throughout different (barrier) tissue sites in the body, where 
they are believed to primarily serve as activators of antigen-specific T-cells in lymph nodes 63 64. 
Amongst a variety of DC subtypes characterized to date, conventional CD11c+ DCs (murine) are 
considered indispensable for the activation of T-cells 65. Under homeostatic conditions, peripheral 
CD11c+ DCs exist in an immature state wherein they specialize in sensing extra-organismal 
presence through phagocytosis or trogocytosis 66. However, upon successful detection of PAMPs 
or DAMPs through PRRs, immature DCs undergo rapid maturation to specialize in antigen 
presentation 67 68. Correspondingly, biomarkers of DC maturation include increased surface 
expression of phagocytosed antigens in MHC complexes, enhanced expression of co-stimulatory 
molecules, such as CD80, CD86 and CD40 and improved secretion of cytokines for the functional 
skewing of cognate T-cell differentiation 69. These functional and molecular programs together 
make (mature) DCs excellent cellular adjuvants in promoting targeted T-cell responses against 
tumor-associated antigens 68. Indeed, DC precursors can be isolated from peripheral blood, 
differentiated and matured into type 1 DCs (producing IL-12, IL-15, IFN-I and IL-23) and loaded 
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with autologous tumor lysates or tumor antigen-derived peptides competent to bind to MHC-I 
molecules in vitro for clinical use as personalized cancer vaccines 70 71.  A variety of human 
melanoma studies have used such DC vaccines loaded (peptide pulsed or adenovirally transduced) 
with autologous tumor or known shared melanoma antigens (MART1, MAGE-A1, MAGE-A3, 
MAGE-A6, gp100, tyrosinase etc.,) to successfully prime melanoma antigen specific CD8+ and 
CD4+ T-cells 70-73. Despite holding significant conceptual promise, a meta-analysis of thirty eight 
independent DC vaccine trials (1996-2007) treating advanced melanoma patients revealed only 
modest clinical benefit (9% CR or PR; RECIST) with treatment 74 75 76. 
1.2.2.2.2 Adoptive cell therapy (ACT) 
Activated cytotoxic T-cells may also be used directly as cellular agents to control cancer 
growth. In a number of clinical trials, robust intratumoral T-cell infiltration correlates with 
objective clinical response, suggesting that the adoptive transfer of autologous, ex-vivo primed 
anti-tumor CTLs may represent an effective therapeutic strategy to supplement endogenously 
generated anti-tumor CTLs in patients 38 77 78. Early efforts using ACT-based interventional 
approaches yielded encouraging success against EBV+ nasopharyngeal carcinoma, where the 
administration of autologous, ex-vivo primed CTLs reactive against EBV antigens induced durable 
(>2 years) disease remission in patients with early-stage posttranslational lymphoproliferative 
disease 79 80. Subsequent advances in computational biology have allowed for the identification of 
shared and unique tumor-associated antigens (TAA), which has furthered the development of ACT 
approaches for solid cancer 81 82. Melanoma especially represents a model cancer type for the study 
and implementation of ACT regimens, given its high mutational burden leading to the accrual of 
immunogenic TAAs (differentiation antigens and overexpressed antigens) or aberrant expression 
of typically oncofetal cancer-testis (CT) antigens 78 83. Indeed, adoptive transfer of CTL reactive 
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against CT antigens such as NY-ESO-184 or melanocyte-differentiation antigens including 
MART1/MelanA 85 and gp100 86 have all shown promising clinical response rates (~35%, 
RECIST), leading to better overall survival and relapse free survival (53.5 months in MART1+ 
ACT cohort vs 3.5 months in MART1- ACT cohort) in treated melanoma patients 85. The high 
mutational burden in melanoma also leads to the development of spontaneous point mutations 
which may manifest as tumor unique, lesion-specific neoantigens 87. Unique neoantigens may 
function as superior therapeutic targets due to their highly-restricted expression in cancer cells 
which reduces concerns for off-tumor toxicities associated with adoptive T-cell therapies. 
Additionally, the development of such unique antigens throughout the course of disease 
progression suggests that neoantigens may be critical to tumor survival and malignancy and 
therefore may serve as an ‘Achilles’ heel’ for targeted rejection of the tumor by the adaptive 
immune system 88-90. Despite these beneficial features, the complexities associated with 
longitudinal profiling 91, validating and directing anti-tumor immunity against such intralesionally 
diverse 92 93 neoantigens expressed variably in tumor clonotypes composing heterogeneous tumor 
lesions, likely diminish their therapeutic utility and impact within the context of current ACT 
regimens. 
Regardless of the type of antigen targeted, several novel strategies have also served to enhance 
the clinical efficacy of ACT-based treatment approaches. Notably, different patient-derived T-cell 
subpopulations are understood to confer different anti-tumor efficacies in ACT trials. Restifo and 
colleagues have elegantly demonstrated that CTLs derived and expanded from autologous central 
memory T-cells (TCM) persisted longer in patients’ peripheral circulation, migrated to SLOs more 
efficiently and reconstituted effector memory (TEM) and TCM more robustly when compared to 
CTLs derived and expanded from autologous TEM 94. Alternatively, other modifications to ACT 
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protocols such as i) immunoregulatory cell depletion using cyclophosphamide, docetaxel and/or 
total body irradiation to ablate Treg and MDSC populations 95 96 and ii) administration of (IL-2R) 
common gamma chain cytokines rhIL-7 and rhIL-15 or bolus high-dose rhIL-2 have been shown 
to  enhance the efficacy of combination ACT regimens 97. 
1.2.2.2.3 Engineered T-cell therapies 
Autologous patient derived T-cells may also be genetically modified using viral vectors to 
express 
receptors allowing for targeted recognition of antigens (over)expressed by tumor cells, leading to 
improved therapeutic benefit. 
1.2.2.2.3.1 Chimeric Antigen Receptor T-cells (CAR-T cells):  
A key limitation associated with endogenous anti-tumor T-cell responses is that CD4+ or CD8+ 
T-cell recognition of tumor cells requires the appropriate presentation of tumor antigens by MHC 
molecules expressed on the surface of cancer cells. This requirement limits T-cell recognition of 
cancer to short, linear peptide epitopes that are ~8-15 amino acids in length which may be 
differentially processed from precursor tumor antigens across individual tumor clonotypes 98. 
CAR-T cells or engineered T-cells expressing a chimeric antigen receptor (CAR) seek to address 
this limitation by directly recognizing the intact extracellular domains of proteins accessible on the 
cancer cell surface. Traditional CARs possess i) an antibody-based extracellular recognition 
domain that allows CAR-T-cells to detect native 3D surface proteins on cancer cells and ii) an 
intracellular signaling domain to promote rapid and robust T-cell activation following antigen 
detection. CAR-T cells may therefore be designed to reject cancer by recognizing both unmodified 
and post-translationally modified tumor-associated surface proteins (such as differentially 
glycosylated tumor proteins) 99. CAR based T-cell technologies offer a flexible platform to expand 
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targetability (by altering the antibody extracellular domain) and fine-tune activity (by altering 
intracellular activation or costimulatory domains) of T-cells against antigenically heterogenous 
diseases like cancer 100. However, since CARs possess antibody-based receptors, CAR-T cells are 
not effective in detecting inaccessible or intracellular tumor-associated proteins and as such, are 
limited to the detection of tumor-associated surface proteins 101. Unfortunately, many cancer-
associated surface proteins are also expressed in varying degrees on normal cells leading to reports 
of on-target off-tumor toxicities in CAR-T-cell-based therapies 102 103. Despite such concerns for 
irAEs, carefully dosed CAR-T cell therapies targeting melanoma-associated proteins GD2, c-Met, 
VEGFR2 and CD70 are currently being tested in phase I/II trials 104. 
1.2.2.2.3.2 T-Cell Receptor Transgenic T-cells (TCR-T cells):  
A second class of engineered T-cells are T-cells engineered to express T-cell receptors (TCRs) 
reactive to MHC-associated tumor peptides. TCR-T cell technologies, unlike CAR-T-cells, 
continue to rely on MHC-restricted recognition of tumor antigens but seek to enhance tumor 
reactivity of autologous T-cell products through the selective transgenic expression of superior 
(high affinity) tumor reactive TCRs. To develop TCR-T cells, polyclonal autologous T-cells are 
first co-cultured with specific pre-determined tumor-associated antigens to identify T-cell clones 
with greatest reactivity against the tested tumor antigen 101. TCRs of the most reactive T-cell clones 
are then sequenced to generate paired-α/β TCR libraries, cloned into viral vectors, and transduced 
into freshly isolated autologous T-cells to generate large numbers of highly reactive anti-tumor 
TCR-T-cells with known anti-tumor specificities 101. TCR-T cells can therefore enhance tumor 
rejection through improved recognition (i.e., high affinity and/or avidity) of MHC-presented tumor 
antigen-derived peptide epitopes 105 106. However, the requirement to first know the identity of 
immunogenic tumor-associated antigens in order to generate TCR libraries, as well as, clinical 
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instances of severe, and sometimes fatal, off-target toxicities using TCR-T regimens 106-108, 
continue to represent major hurdles for the clinical advancement of these T-cell modalities as a 
potential standard of care treatment for solid cancers. Despite these challenges, several anti-
melanoma TCR-T cell products including those recognizing MART-1, gp100, NY-ESO-1 and 
MAGE-A3 are being evaluated in phase I/II clinical trials 101. 
1.2.2.3 Immune checkpoint blockade antibodies 
The immune system protects against tumorigenesis through a finely tuned series of checks and 
balances where inflammatory ‘on’ cues such as MHC-TCR, B7-CD28 and cytokine signals 
facilitate tumor protection mechanisms, while ‘off’ or tolerance programs protect against excessive 
autoimmune damage. In this regard, there exists two levels of immune tolerance; central tolerance 
mechanisms which function at the level of lymphocyte selection in primary lymphoid organs and 
peripheral tolerance mechanisms which function as a rheostat to prevent self-toxicity at peripheral 
sites of chronic inflammation. Immune cells such as Tregs, MDSCs and TAMs, and surface 
checkpoint proteins such as PD-L1/PD-1 and CTLA-4 represent a few key mediators involved in 
peripheral tolerance and unsurprisingly, these are often hijacked by the tumor to facilitate tumor 
progression. Each of these cells and axes therefore serve as key targets in interventional approaches 
to enhance the efficacy of therapeutic peripheral anti-tumor T-cell responses. Specifically, 
neutralizing antibodies against the immune checkpoint molecules PD-1 and CTLA4 have 
revolutionized cancer immunotherapy since receiving FDA approval in 2011 and these agents are 
briefly discussed below: 
1.2.2.3.1 Anti-CTLA4 
Cytotoxic T Lymphocyte Associate protein 4 (CTLA4) is an activation-induced surface 
molecule that mediates peripheral tolerance of T lymphocytes 109. CTLA4 is upregulated acutely 
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within 2-3 days of TCR activation 110 and serves as a direct competitor for costimulatory CD28 
ligands, B7-1 (CD80) and B7-2 (CD86), which are canonically expressed by mature APCs 111. 
Based on a 4-fold increased affinity for B7-1/2 112-114, CTLA4 directly outcompetes CD28 for 
binding to costimulatory ligands, thereby preventing proximal TCR signaling 115 116. In this regard, 
CTLA4 neutralizing antibodies have been designed to enhance activation of tumor infiltrating T-
cells in solid malignancies including melanoma. Ipilimumab (Yervoy), the human monoclonal 
antibody raised against CTLA4, was approved for clinical use in 2011, with results from phase II 
trials in patients with advanced melanoma an overall response rate of 17% (23 of 139 patients) 117. 
Notably, three patients developed complete or durable responses for up to 53 months post-
treatment 117.  Furthermore, overall survival in treated patients was extended to ~16 months, 
however effective treatment often coincided with severe irAEs such as enterocolitis and 
hypophysitis 38 118. 
1.2.2.3.2 Anti-PD-1 
In contrast to CTLA4 which functions as a sink for costimulatory ligands, Programmed Death-
1 (PD-1) is an inflammation-induced immunomodulatory receptor that is expressed on activated 
T-cells, serving to limit proximal TCR signals at peripheral sites of chronic inflammation 119. PD-
1 ligands, namely PD-L1 and PD-L2, are promptly upregulated on APCs, stromal cells and tumor 
cells in response to IFNγ 120 and these counter-regulate T-cell activation via their interaction with 
PD-1+ T-cells where ligation of PD-1 subsequently recruits and activates the TCR phosphatases 
SHP1/2 to ablate CD3ζ-TCR signaling 121-123. The importance of PD-1 in the maintenance of 
homeostasis is evidenced by the development of severe autoimmunity including SLE and 
cardiomyopathy in Pdcd1 allelic knockout animal models 124 125. While acute expression of PD-1 
serves as a marker of T-cell activation, the chronic expression of PD-1 is also associated with the 
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increased expression of T-cell exhaustion markers TIM3 and LAG3 126. PD-1 activation can also 
limit T-cell function by skewing T-cell metabolism in favor of fatty acid oxidation, which slows 
T-cell proliferation and lowers TEM production of cytokines and tumoricidal proteins such as 
perforin 127 128. Given these deleterious effects in PD-1 signaling in T-cells, Nivolumab (Opdivo), 
a neutralizing human antibody against PD-1, was approved for clinical use in 2014 and has since 
shown great promise in numerous trials. Since PD-L1 is expressed at sites of inflammation, 
Nivolumab mediates therapy benefit by reinvigorating exhausted intratumoral T-cells, supporting 
the prerequisite that patients have pre-existing tumor infiltrating lymphocytes (TILs) for optimum 
clinical response to PD-1 blockade regimens 129 130.  Indeed, recent studies by Ribas et al. support 
this paradigm, since beneficial clinical outcome to Nivolumab correlates with the presence of 
intratumoral CD8+ T-cells pre-therapy and with enhanced TCR clonality on-treatment, suggesting 
that Nivolumab induces the clonal expansion of pre-existing TIL within the TME 130; an effect that 
has also been observed in other solid tumors such as NSCLC 131. 
Together, blockade of the PD-1 axis induces therapeutic anti-tumor responses by rescuing 
exhausted T-cells via the restoration of proximal TCR signaling, leading to the reinvigoration and 
expansion of pre-existing TIL within the TME. 
1.3 Challenges in current treatments for melanoma 
1.3.1 The tumor microenvironment: an immune desert 
Despite the availability of diverse treatment modalities, many cancer patients fail to respond to 
therapeutic intervention. It is therefore critical to evaluate whether the major roadblock to existing 
therapies can be attributed to the generally poor immunogenicity of tumors 132, to the insufficient 
activation of therapeutic anti-tumor T-cells 133 134 and/or to the inefficient mobilization/recruitment 
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of effector T-cells into the TME 135 to reformulate and improve the therapeutic design of next-
generation protocols.  
Early studies by Klein and colleagues shed light on this question by showing that activated anti-
tumor T-cells are indeed found in the draining lymph nodes of MCA sarcoma-bearing mice shortly 
after tumor engraftment 89. Interestingly, these tumor reactive T-cells do not limit the growth of 
the established primary tumor, but are competent to reject subsequent tumor challenges, suggesting 
that established tumors develop a ‘barrier-like’ microenvironment that limits T-cells access into 
the TME 89. Boon and colleagues further show that the majority of melanoma patients indeed have 
detectable levels of anti-MAGE-A1 T-cell clones in their peripheral blood, suggesting that 
melanomas are indeed immunogenic and that they can be successfully recognized by the immune 
system under appropriate conditions 136. Finally, Rosenberg and colleagues noted melanoma 
recurrence in the absence of emerging antigen-loss variants, even amongst clinical responders in 
a DC-based vaccine trial, implicating that tumor-extrinsic, microenvironmental factors contribute 
to the observed acquired therapy resistance 137. These findings suggest that treatment-resistant 
TMEs support tumor progression in part by strongly impeding recruitment of anti-tumor T-cells. 
Indeed, Galon and colleagues have elegantly shown that in solid cancers, the exclusion of tumor 
reactive T-cells from the tumor parenchyma correlates negatively with clinical outcome138. 
Regardless of the type of treatment, the exclusion of T-cells from the tumor compartment 
represents a major mechanism underlying poor clinical response amongst patients with melanoma. 
1.3.1.1 T-cell exclusion in targeted therapy 
Melanoma progression is driven by activating BRAF mutations15 in 35% of cases and loss-of-
function PTEN mutations139 in 10% of cases, where both of these mutations impede T-cell 
infiltration into the TME. First, melanoma patients harboring oncogenic BRAF mutations 
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demonstrate the poorest infiltration of endogenous 140-142 T-cells and adoptively transferred ACT 
products, suggesting an inverse relationship between oncogenic BRAF activation and intratumoral 
T-cell infiltration.  Besides activating pro-tumorigenic MAPK signals, the most common 
BRAFV600E mutation also upregulates local VEGF production 143 which hinders T-cell infiltration 
by promoting dysfunctional angiogenesis and/or dense ECM polymerization 135 144 145. In this 
regard, treatment of melanoma with inhibitors that disrupt the BRAF signaling cascade 
(Dabrafenib and Vemurafenib (BRAF inhibitors) or Trametinib (MEK inhibitor)) substantially 
enhances  melanoma antigenicity 146 and/or immunogenicity 147, leading to improved infiltration 
of and immunosurveillance by endogenous and/or adoptively transferred T-cells 140 148-150. 
Furthermore, PTEN-/- mutations often synergize with BRAFV600E mutations 35 to limit T-cell 
infiltration. Hwu et al. recently confirmed this relationship in pre-clinical models as well as in 
TCGA melanoma cohorts where PTEN copy number correlated positively with CD8+ T-cell 
infiltration, and intratumoral granzyme B/IFNγ expression 151. Mechanistically, Pten-/- mutations 
also activate PI3K to further facilitate T-cell exclusion 152. In the case of BRAFV600E Pten-/- 
melanomas, TIL content can be partially rescued by administration of PI3Kb inhibitors 151.  
Although such inhibitors hold substantial therapeutic promise, melanoma lesions quickly 
develop acquired resistance in the majority of patients treated with BRAF inhibitors (BRAFi) 
based on de novo development of secondary mutations in BRAF, or in MAPK proteins, which via 
mechanisms discussed above, continue to sponsor a T-cell sparse TME 153-155.  
1.3.1.2 Melanoma exclusion of adoptively transferred T-cells 
The adoptive transfer of autologous tumor-reactive T-cells represents another promising 
treatment modality for the treatment of patients with melanoma. While ACT approaches 
significantly extend overall survival in clinical responders, a significant proportion of patients do 
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not respond nor benefit from such therapeutic cell transfers. Accordingly, Ganss et al. and 
Rosenberg et al. demonstrated that resistance to ACT treatments can indeed be attributed to the 
poor infiltrating yield (~1-10%) of transferred T-cells into the TME in murine models of 
neuroendocrine cancers and melanoma, respectively 156 157. In stark contrast, adoptively transferred 
T-cell regimens have exhibited significantly greater success in hematologic malignancies, which 
typically lack a physical/compartmental barrier-like microenvironment as is characteristic of solid 
cancers, including melanoma 158 159. These findings suggest that solid tumors progress, even in the 
presence of abundant circulating tumor-reactive T-cells through the effective barricading of T-
cells from entering the TME or lack of signals that bring T-cells into the TME.  
1.3.1.3 Exclusion in immune checkpoint blockade 
T-cell exclusion observed within solid cancers such as melanoma also poses a significant 
challenge to the effectiveness of T-cell reinvigoration therapies, such as checkpoint blockade 
strategies. In a landmark study investigating drivers of clinical outcome in metastatic melanoma 
patients receiving Nivolumab, a PD-1 immune checkpoint blockade (ICB) antibody, Ribas and 
colleagues determined that baseline density of TIL prior to ICB therapy was highly predictive of 
treatment outcome wherein progressors in the trial demonstrated the poorest infiltration of T-cells 
prior to, and throughout the course of treatment 160. In contrast, positive response to PD-1 ICB was 
associated with increased TIL clonality on-treatment, suggesting that the observed therapeutic 
effect with ICB was due to the reinvigoration and clonal expansion of TILs within the TME 160 161. 
Therefore, important findings from these studies suggest that reversing T-cell exclusion prior to 
administration of checkpoint therapy may be required for optimal efficacy of ICB 162.  
Therefore, an important question arises in how tumors exclude T-cells to evade 
immunosurveillance, with one possible answer reflecting disease-associated defects in the tumor 
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endothelium. Since blood vessels provide circulating T-cells access to the TME and given that 
tumor angiogenesis leads to severe vascular dysfunction in solid cancers, the tumor-associated 
vasculature can serve as a principal suspect in preventing T-cell infiltration into the TME. The 
following section addresses the unique structural and functional properties of the tumor 
vasculature that further support/establish this idea. 
1.3.2 The tumor-vascular endothelial barrier 
Vascular networks serve as conduits through which peripheral antigen-experienced T-cells gain 
access to inflamed tissues. The rapid development of neovascular networks is a critical pathologic 
feature that facilitates tumor growth and is accordingly recognized as one of the hallmarks of 
cancer progression 163. Since blood vessels serve as the primary highways for T-cell entry into 
tissues, T-cell exclusion in solid tumors may be attributed to the unique characteristics of tumor-
associated blood vessels, whereby a critical understanding of vascular phenotypic differences 
linked to immune cell exclusion could lead to targeted approaches for improved TIL entry into the 
TME.  
1.3.2.1 Pathologic properties of the tumor vasculature  
Tumor angiogenesis is triggered by a simple imbalance in oxygen consumption versus oxygen 
supply. Oxygen consumption by the growing tumor mass often supersedes the rate of oxygenation 
by endogenous blood vessels feeding the growing lesion, resulting in local tissue hypoxia 164. 
Hypoxia-associated proteins, such as Von Hippel Lindau Factor (VHL), and hypoxia-inducible 
transcription factors, such as HIF1α and HIF2α 165-167 in turn promote local production of vascular 
endothelial growth factors, including VEGFA, which supports neoangiogenesis and improved 
local tissue oxygenation upon binding to its cognate receptors VEGFR1/2 168. This key process 
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known as the “angiogenic switch”, is critical in the conversion of avascular neoplasia into highly-
vascularized, progressive tumors 169.  
Angiogenesis under homeostatic conditions is a carefully regulated process characterized by 
controlled cell-cycle checkpoints, orchestrated interactions between endothelial and mural 
populations 170 171,  and the development of tight intercellular junctions 172 173, all of which are  
commonly dysregulated in the hypoxic TME 169. Developmental flaws in endothelial cells that 
arise due to an unsupervised proliferation give rise to key differences in these vascular networks 
that negatively affect T-cell recruitment and function within the TME 174.  
Morphologically, newly formed tumor-associated blood vessels have large diameters, exhibit 
random branching and develop poor cell-cell adhesion between contiguous endothelial cells and 
abluminal mural pericytes 175 176. These defects lead to the formation of large, porous and leaky 
vessels which severely limit luminal blood flow for optimal delivery of drugs, immune cells and 
oxygen into the TME, and the clearance of immunosuppressive metabolic waste products from the 
TME 175 176. Furthermore, leaky tumor-associated blood vessels also lead to increased local 
interstitial fluid pressure 177, which serves as an environmental (i.e. pressure gradient) barrier for 
T-cell penetrance into the diseased tissue. Through the combined effects of poor vascular flow and 
large pores, plasma and luminal blood pool in large vascular reservoirs leads to only limited 
seepage of circulating fluid contents into the TME. This phenomenon, together with an 
underdeveloped network of draining lymphatics within the TME, leads to further increases in the 
tissue interstitial fluid pressure (IFP), resulting in vessel collapse and further constraint on tissue 
perfusion in the face of reinforced hypoxia in the TME. 
Tumor blood vessels also harbor key molecular differences that facilitate tumor immune 
evasion through T-cell exclusion. Of note, tumor vessels differentially upregulate expression of 
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apoptosis-inducing Fas Ligand (FasL), creating a harsh luminal microenvironment for perfusing 
Fas+ TEM 178-180. Under these conditions, Tregs demonstrate greater intrinsic resistance to apoptosis 
than effector CD8 T-cells by virtue of their expression of elevated levels of the anti-apoptotic 
protein, cFLIP 181. Additionally, tumor vessels also actively recruit Tregs via expression of the 
Treg homing ligand Common Lymphatic Endothelial and Vascular Endothelial Receptor 
(CLEVER) 182. Furthermore, endothelial VEGFA-VEGFR2 and endothelin-1(ET-1)-ETR 
signaling cascades downregulate the endothelial adhesion molecules Vascular Cell Adhesion 
Molecule 1 (VCAM1) and Intercellular Adhesion Molecule 1 (ICAM1), which also limits the 
recruitment of activated Very Late Antigen-4 (VLA4)+, Lymphocyte function-associate antigen 1 
(LFA1)+ cytotoxic CD8 T-cells 157 183. When taken together, these vascular-centric molecular 
alterations result in therapeutically contraindicated increased Treg:CD8 ratios in the TME of solid, 
vascularized cancers. 
Therefore, tumor-associated vs. normal tissue blood vessels are structurally and functionally 
aberrant, and operationally skewed to impede effector T-cell trafficking into the TME (Fig. 1). 
1.3.3 Therapeutic reprogramming of the solid tumor vascular network to improve T-cell 
infiltration 
1.3.3.1 Normalizing existing tumor vasculature 
Given that the abnormal tumor vasculature exacerbates disease pathology, one might expect 
that interventional strategies that antagonize tumor angiogenesis would give rise to a ‘normalized’ 
tumor vasculature characterized by an improved ability to recruit/sustain anti-tumor immune 
responses within the TME.  
Since VEGFA is a major driver of tumor angiogenesis, vessel-associated pathologies (as 
discussed above) could theoretically be ameliorated by limiting VEGF bioavailability within the 
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TME 184.  Furthermore, tumor blood vessels express unique, tumor-associated antigens which 
could also be used to selectively deplete abnormal tumor associated vessels in support of 
therapeutic re-vascularization by normal endothelial cells leading to the restoration of normal 
homeostatic vascular behavior 185 186. Besides limiting T-cell infiltration through induced 
biophysical barriers, tumor endothelial cells are poor expressors of lymphocyte adhesion 
molecules VCAM1 and ICAM1, which are essential for the recruitment of LFA-1+VLA-4+ 
effector T-cells. In this regard, inflammatory stimuli, such as IFN-I and TNFα, known to 
upregulate VEC expression of VCAM1 and ICAM1, may potentiate normal vascular function 
within the TME 187 188.  
Therefore, vascular normalizing strategies may potentiate anti-tumor responses within the 







Figure 1: Structural and functional characteristics of constitutive vs. therapeutically normalized 
blood vessels and their impact on immune cell recruitment into the TME  
Pictorial comparison of the untreated tumor vasculature vs. the therapeutically normalized tumor 
vasculature. TME with untreated vasculature are characterized by enhanced vessel permeability 
leading to increased tissue hypoxia and IFP. Endothelial cells (EC) in the untreated TME are also 
associated with poor EC-EC adhesion, poor EC-pericyte interaction and enhanced endothelial 
expression of Fas Ligand (FasL), Endothelin Beta Receptor (ETbR), Common Lymphatic 
Endothelial and Vascular Endothelial Receptor (CLEVER) and Vascular Endothelial Growth 
Factor 2 (VEGFR2). The vasculature in the normalized TME demonstrates improved vessel 
integrity, vessel perfusion and tissue normoxia. ECs in normalized TME are tightly associated with 
other ECs and with abluminal pericytes, and they express elevated levels of the effector T-cell 
adhesion molecules Vascular Cell Adhesion Molecule 1 (VCAM1) and Intracellular Adhesion 
Molecule 1 (ICAM1). 
1.3.3.1.1 Targeting VEGF signaling for vascular normalization (VN) 
VEGFA is produced in large quantities within the TME of solid tumors and is well known for 
its role in promoting dysregulated tumor-associated angiogenesis 189-191. This suggests that 
VEGFA is a central player in sponsoring an aberrant vasculature, and that by limiting the 
bioavailability VEGFA in the TME, one might predictably reverse angiogenesis-associated 







monoclonal antibodies, including the first-generation murine antibody A4.6.1 and its humanized 
monoclonal successor, Bevacizumab (Avastin), that have ultimately been shown to normalize the 
tumor vasculature 193 194.   
In murine models of GBM, melanoma and colorectal carcinoma. Jain and colleagues 
demonstrated that the intratumoral delivery of A4.6.1 resulted in the normalization of the tumor 
vasculature as characterized by reduced microvessel density, reduced vascular permeability, 
reduced tumor interstitial fluid pressure, improved vessel perfusion and improved tissue normoxia, 
suggesting that VEGF/VEGFR blockade indeed normalizes blood vessels in the TME 193 195 196. 
Bevacizumab conferred similar therapeutic changes to the tumor vasculature in humanized mouse 
models of neuroblastoma, breast cancer, melanoma, and ovarian cancer and in melanoma patients. 
197 198. Furthermore, in melanoma patients, treatment with Bevacizumab and Ipilimumab 
demonstrated therapeutic synergy (vs. either monotherapy) in association with normalized blood 
vessels, an improved degree of intratumoral T-cell infiltration and a median overall survival of 
25.1 months 199 200.  
These findings suggest that abnormal tumor vessels can be normalized by limiting VEGF 
activity within the TME, either directly by removing the bioactive VEGF ligand, or indirectly via 
enhanced local production of natural VEGFR2 antagonists such as VEGI (also known as 
TNFSF15) 201. Ultimately, such therapeutic changes in the tumor vasculature may facilitate the 
recruitment and retention of impactful levels of therapeutic TIL. 
1.3.3.1.2 Vaccines targeting tumor blood vessel antigens to promote VN  
Cancer cells accrue a significant number of mutations during the oncogenic process and as such, 
they express starkly different gene expression profiles from their normal healthy counterparts. 
Although less appreciated, stromal cells (including vascular cells) are also subject to aberrant 
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growth conditions within the TME (i.e. hypoxia, acidosis, high IFP) that can alter their epigenetic 
programming. Indeed, gene set enrichment analyses of tumor-derived endothelial cells and 
pericytes have identified tumor-associated overexpression (i.e. 10-500 fold) of blood vessel 
antigens (TBVA) such as TEM1 202 203, DLK1 204 205, DLK2 205, HBB 206, EphA2207, RGS5 208 and 
NRP1 209 that allow for differential recognition of tumor vs. normal tissue-associated 
VEC/pericytes by antigen-specific CD8+ T-cells. These TBVA have been successfully integrated 
into prophylactic/therapeutic DC- and DNA-based vaccines to instigate differential T-cell-
targeting of tumor blood vessels. This strategy is designed to fortify tumor vasculature by 
promoting immune-mediated “trimming” and local development of a proinflammatory TME.  
Indeed, therapy using DC/TBVA-based vaccines in pre-clinical models of melanoma, colon 
carcinoma and lung cancer supports the therapeutic relevance of vascular normalization since the 
delay in tumor growth is associated with reduced tumor vascular density, improved tumor vessel 
functionality and enhanced infiltration of tumor reactive- and/or TBVA reactive- T-cells within 
the TME on-treatment. Through performance of a pilot phase II clinical trial, our group has also 
demonstrated the efficacy of this DC/TBVA peptide-based vaccine in normalizing the vasculature 
and the TME in HLA-A2+ patients with metastatic melanoma, wherein we also observed a robust 
expansion of TBVA-specific T-cells in peripheral blood selectively in patients with objective 
clinical responses (Chelvanambi et al., manuscript in preparation). Interestingly, objective clinical 
response on this trial was also associated with epitope spreading in the T cell response of clinical 
responders, since over the course of treatment these patients developed an expanded repertoire of 
T-cells reactive against a number of vaccine-unrelated but melanoma-associated antigens. These 
findings suggest that vascular normalization, by improving initial T-cell mediated tumor apoptosis, 
may also support the release of new tumor associated antigens (TAA) that can be subsequently 
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internalized and cross-presented by endogenous APCs (in draining lymph nodes) to ultimately 
diversify the overall immune recognition of cancer. In unrelated studies, DNA-based vaccines 
targeting other TBVAs such as VEGFR2/Flk1210 211 and TEM1/CD248 212, have also shown 
significant pre-clinical promise in normalizing the tumor vasculature (increased vascular 
perfusion, decreased vascular leakage, decreased microvessel density) and promoting the 
intratumoral infiltration of tumor specific CD8+ T-cells in animal models of melanoma, and 
carcinomas of the breast, colon and lung.  
This suggests that vaccine-induction of T-cells that selectively react against tumor-associated 
endothelial cells/pericytes may promote vascular normalization, leading to corollary cross-priming 
of vaccine unrelated, but therapeutically meaningful anti-tumor T-cells that are effectively 
recruited into the proinflammatory TME post vaccination.  
1.3.3.1.3 Metronomic chemotherapy for VN 
The core therapeutic principle of several classes of chemotherapeutic drugs is that they target 
cells with high proliferative potential, leading to selective death of tumor vs. normal cells in vivo. 
Despite this rationale, interspersed, near-MTD doses of chemotherapy have largely failed in the 
clinic, with seminal work by Judah Folkman and colleagues demonstrating that relapse is common 
with traditional dosing/scheduling regimens because surviving cancer cells retain their 
proliferative ability and continue to expand rapidly in the long-intervals between drug doses 213. 
Instead, they proposed that repetitive sub-MTD doses of the same chemotherapeutic agent, i.e., 
metronomic chemotherapy (MCT), would confer better therapeutic benefit by more effectively 
enforcing sustained selective (apoptotic) pressure on rapidly dividing cancer (and stromal cell 
populations) cells within the TME 213. Interestingly, while many cancer cells quickly develop 
resistance to chemotherapeutic drugs 214, rapidly proliferative tumor-associated endothelial cells, 
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but not normal endothelial cells, remain sensitive 215 216 to most forms of chemotherapy. This 
suggests that MCT approaches, through largely anti-angiogenic mechanisms, could lead to 
structural and functional normalization of the tumor vasculature. Indeed, several groups have now 
shown that metronomic dosing of cytostatic chemotherapies (i.e. paclitaxel 217 218, capecitabine 219 
and cyclophosphamide 213), cytokine therapies (IFNα 220), and radiation therapy 221 can all lead to 
normalization of the tumor vasculature in association with delayed tumor growth in pre-clinical 
models of cancer. 
These examples highlight a range of interventional approaches that may be invoked to promote 
conditional vascular normalization, leading to a pro-inflammatory TME and robust infiltration by 
tumor-reactive T-cells for improved treatment outcome. 
1.3.3.2 Therapeutic induction of a specialized vasculature in the TME for enhanced clinical 
benefit.  
1.3.3.2.1 High endothelial venules and tertiary lymphoid structures 
 
Figure 2: High endothelial venules (HEV) and local immune cell recruitment/function and TLS 
formation in peripheral tissues 
A. The induction of HEVs from flat endothelial cells (EC) is mediated by activation of EC-surface 
LTβR by surface LTα3 or LTα1β2 expressed on tumor infiltrating immune cells. During 
embryogenesis, LTi cells also contribute in the lymph node anlage. B. HEVs subsequently sponsor 
the formation of non-classical/immature (T-cell rich, B-cell devoid) or classical/mature (GC B-




Besides normalizing the pre-existing vasculature, one may also improve immune cell 
infiltration into the TME by inducing the development of high endothelial venules (HEV). HEVs 
are a class of specialized endothelial cells that are canonically found within secondary lymphoid 
organs (SLOs) such as the spleen and lymph node 222. HEVs follow a unique developmental 
program where continuous LTβR stimulation confers special morphological features and 
physiological roles when compared to normal, flat vascular endothelial cells (Figure 2) 223. HEVs 
are distinguishable by the presence of tall, cuboidal endothelial cells and expression of specialized 
adhesion molecules MAdCAM1 and PNAd that selectively recruit CD62L+ naïve T/B-cells or TCM 
cells 224-226. However, other immune cell types including cDCs, pDCs and NK cells have also been 
shown to utilize HEVs to infiltrate lymphoid tissues 227 228. Interestingly, HEVs also develop 
spontaneously in highly immunogenic solid cancers and confer a virtually universal positive 
prognostic index when observed 229 230. In this regard, intratumoral HEV density also correlates 
positively with the number of intratumoral T and/or B-cells suggesting that these specialized 
vessels further improve immune access to the tumor 231-233. In peripheral tissues with chronic 
inflammation such as cancer, HEVs may also be found proximal to clonally expanded T and/or B 
lymphocytes and APCs to form tertiary lymphoid structures (TLS); a non-encapsulated functional 
equivalent of SLOs. TLS demonstrate significant contextual and compositional diversity and have 
been commonly profiled either via germinal center B-cell zones232 234 235, T-cell zones, HEVs 236-
238 and/or a LN-like gene signatures 239 where in each instance, these TLS associated biomarkers 
have predicted a positive clinical response in human cancer 230 240. 
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Therefore, HEV neovascularization, in isolation or in association with mature TLS, imparts 
therapeutic value by first promoting robust immune recruitment and subsequently facilitating the 
local expansion of unique anti-tumor T and/or B-cell repertoires within the TME. 
The following sections highlight a few key concepts in HEV/TLS neogenesis. 
1.3.3.2.2 SLOs vs TLSs 
Characteristic SLO TLS 
Structure Encapsulated organs Non encapsulated aggregate of 
immune cells 
Formation Preprogrammed during ontogenesis Formed as a result of chronic 
inflammation 
Anatomy Specialized and found at 
predetermined anatomical locations 
Develop in peripheral tissues and 
demonstrates high degree of 
plasticity 
Lifespan Lasts through lifetime of organism Highly transient and resolve over 
time with discontinuation of 
inflammation 
Vasculature Intricate crosstalk between vascular 
networks of HEVs, afferent and 
efferent lymphatic vessels 
Varied involvement of HEVs and 
uncharacterized involvement of 
lymphatic vessels 
Table 1: Notable differences and similarities between SLO (lymph node, spleen) and TLS 
* summarized from Pimenta et al. 241 
1.3.3.2.3 Types of TLS 
Type Classical TLS Non-Classical TLS 
Cellular composition Contains: GC B-cells, T-cells 
(CD4+, CD8+), TFH, DCs, 
FDCs, HEVs 
Contains some parts of 
classical/mature TLS; often 
lacking GC foci 242 
Spatial arrangement Distinct B (BCL6+) and T-cell 
zones surrounded by HEVs, 
interdigitating presence of 
FDCs and TFHs 
Zones of CD4+/CD8+ T-cells 
and CD11c+ APCs proximal 
to HEVs 
Table 2: Features of different types of TLS 
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1.3.3.2.4 Cellular mediators of HEV and/or TLS neogenesis in cancer 
While the roles and molecular identities of SLO inducing LTi cells are well characterized, the 
identification of a defined cell type with a similar pivotal role/central function in HEV/TLS 
neogenesis remains elusive. Nonetheless, several cell types have been implicated in TLS formation 
in cancer and the evidence of their role in supporting HEV and TLS formation is briefly discussed 
below: 
1.3.3.2.4.1 DCs  
Besides serving as professional antigen presenting cells, DCs play functionally important roles 
in shaping the inflammatory microenvironment of the tumor. In this regard, DCs have 
demonstrated the ability to produce cytokines necessary for the formation of TLSs and their 
footprint within the TME positively correlates with TLS formation in several human cancers. In 
breast cancer, DC-LAMP+ mature DCs were found to be the major producers of LTβ in the TME 
where LT+ mature DC infiltration was strongly associated with increased HEV density and T and 
B-cell infiltration 243. Mature DCs also organize such structures in renal cell carcinoma where an 
increased count of DC-LAMP+ CD80+ CD86+ mature DCs was associated with increased HEV 
density and improved T-cell infiltration 244. Separately, our group has previously demonstrated 
that in situ vaccination of MCA sarcomas and MC38 colon carcinomas with Tbet or IL-36γ 
expressing mature DCs also promotes the formation of HEVs and non-classical TLS within the 
TME 237. Together, these observations implicate conditionally activated mature DCs as instigators 
in the formation and maintenance of HEVs and TLS in the cancer setting. 
1.3.3.2.4.2 NK cells and effector T-cells 
NK cells and T-cells are also implicated in HEV/TLS neogenesis. In elegant studies conducted 
by Peske et al., NK cells and cytotoxic CD8+ T-cells were shown to play separate but sometimes 
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redundant roles in TLS formation within different sites of cancer 245. HEV induction was shown 
to be controlled strictly by LTα3+ CD8+ T-cells in intraperitoneal melanoma lesions whereas both, 
IFNγ+ NK cells and LTα3+ CD8+ T-cells were determined as necessary for HEV formation in 
subcutaneous melanoma models 245. While these results implicate NK cells and effector T-cells as 
relevant and important mediators of HEV/TLS neogenesis, they also highlight the possible 
mechanistic differences underlying the induction of these structures in solid tumors located in 
disparate anatomic locations within the body.  
1.3.3.2.4.3 Removal of Tregs 
Furthermore, immunosuppressive cells may be expected to inhibit HEV/TLS neogenesis by 
mitigating local tissue inflammation. In pre-clinical studies performed with MCA sarcomas, 
targeted depletion of Tregs (using FoxP3DTR mice) conferred superior tumor rejection in 
association with a significant improvement in tumor infiltration by CD4+ and CD8+ T-cells  236 238. 
Hindley et al., postulated that changes to the tumor vasculature might underlie the robust 
lymphocytic infiltration observed upon depleting peripheral Tregs 238. Indeed, tumors from Treg-
deficient mice demonstrated a significant increase in, both, the density of intratumoral HEVs and 
the relative abundance of TLS inducing homeostatic chemokines and lymphotoxins within the 
TME vs control animals. Furthermore, in correlative analysis, HEV density was both inversely 
related to the tumor growth rate and directly related to the number of TNFα+ T-cell infiltrates, 
which were independently shown to maintain HEV morphology through feed-forward TNF 
signaling events 236. This suggests that Tregs function as a rheostat for TLS formation and that 
their targeted depletion could also favor HEV and TLS neogenesis in the TME. 
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1.3.3.2.5 Strategies to induce HEVs and/or TLS in peripheral tissues 
1.3.3.2.5.1 Lymphotoxins and LIGHT  
TNF superfamily members including lymphotoxins and TNFSF14 (also known as LIGHT) play 
crucial roles in the induction of TLS 246. The forced overexpression of LTα under the rat insulin 
promoter (RIPLT) and its cognate expression in kidney and pancreatic tissues promoted the 
formation of lymphocytic aggregates enriched in T-cells, B-cells and APCs in association with 
extensive reprogramming of the tumor vasculature as evidenced by increased expression of 
VCAM, ICAM, MAdCAM and PNAd 247. Furthermore, RIPLT mice also demonstrated elevated 
levels of SLC (CCL21) and BLC (CXCL13) in renal and pancreatic tissues suggesting the central 
TLS-inducing potential of LTα 248. However, the TLS promoting effects of LT are amplified 
through the combined overexpression of LT (as RIPLTαβ mice demonstrate a significant increase 
in HEV abundance), infiltration of naïve lymphocytes and elevated expression of homeostatic 
chemokines compared to RIPLT mice 249. Seminal studies performed by Schrama et al. showed 
that the targeted overexpression of LT also promotes HEV and TLS formation in cancer. Briefly, 
by administering a tumor antigen-specific GD2 scFv-LT fusion protein in mice harboring 
B16.F10 melanoma, Schrama et al. demonstrated that therapy associated with LT overexpression 
resulted in an increased intratumoral HEV density and the development of a diverse T-cell 
repertoire in association with the presence of TLS 250. In addition, in breast cancer models, LT 
expression by intratumoral DCs correlated positively with HEV density, suggesting that LT also 
independently drives HEV/TLS neogenesis 243. However, the biology of LT and LT converges 
at the level of their cognate receptor, LTβR, whose central role in HEV/TLS neogenesis can be 
appreciated through the loss of such structures when Ltα/Ltβ is administered in combination with 
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competitive blocking LTβR-Ig proteins 251 252. Additionally, LT and TNF signaling axes 
demonstrate a certain degree of crosstalk since soluble LTα3 homotrimers also induce HEV 
development via activation through TNFRI rather than LTR 236 245.  
Another related TNF family member protein, TNFSF14 (also known as LIGHT), also 
contributes to TLS formation in cancer. LIGHT produced by immune cells activates the surface 
receptor HVEM and to a lesser extent, LTβR, to induce early events in SLO organogenesis. Recent 
evidence suggests that it plays a similar role in TLS organogenesis. In a study carried out by 
Gantsev et al., newly formed lymph nodes in freshly resected breast cancer tissue exhibited a 
significant increase in local expression of TNFSF14 vs. adjacent mature lymph nodes within the 
tumor tissue, suggesting that LIGHT serves as an early inducer of ectopic lymphoid organogenesis 
253. To further elucidate the role of LIGHT in TLS formation, Ganss et al. delivered LIGHT to 
blood vessels through a vascular targeting peptide and observed the de novo induction of classical 
TLS together with increased vascular normalization within the TME, thus suggesting that 
activation of HVEM and/or LTβR by LIGHT on VECs is sufficient to induce formation of cuboidal 
HEVs and classical TLS in solid cancers 233. Additionally, forced expression of LIGHT in a murine 
model of fibrosarcoma led to the therapeutic rejection of tumors which occurred in association 
with an increased infiltration of naïve lymphocytes and increased local production of homeostatic 
chemokines 254 255. Together, the LTα1β2/LIGHT-LTβR, LTα3-TNFRI and LIGHT-HVEM 
signaling axes represent key targets for the ectopic induction of local TLS formation in cancer 
lesions. 
1.3.3.2.5.2 IFN-I  
Type I interferons are another class of cytokines implicated in the formation of HEV/TLS. In 
studies analyzing the role of IFNβ in pulmonary GC formation in response to Influenza A Virus 
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(IAV) infection, a subset of PDGFRα+ lung fibroblasts were identified as major producers of 
CXCL13 in response to intranasal transfusion of IFNβ 256. The in vivo activation of IFNAR in 
these fibroblasts enhanced intrapulmonary CXCR5+ B-cells+ TLS formation which collectively 
promoted the development of a more broadly neutralizing repertoire of antiviral antibodies capable 
of conferring cross-strain protection when compared to TLS-deficient animals exhibiting greater 
susceptibility when burdened with diverse strains of IAV 256 257. Furthermore, IFN-I production by 
activated DCs was positively correlated with worsened clinical score, increased autoantibody 
production and TLS formation in a hydrocarbon (TMPD)-induced model of autoimmune SLE 258 
259. Additionally, IFN-I-IFNAR signaling sponsors HEV/TLS neogenesis by promoting the 
production of several known TLS nucleating factors such CXCL10/11 260 and lymphotoxins 261 
via feed-forward signaling loops. Therefore, the administration of IFN-I, either directly or 
indirectly by activating other signaling cascades, may condition the TME for local HEV and TLS 
neogenesis. 
1.3.3.2.5.3 TNFR1 agonism 
TNF receptors are expressed on endothelial cells and function as key signaling nodes for 
endothelial proliferation and function. In studies performed by Peske et al., expression of TNFR1/2 
receptors on endothelial cells was highlighted to be necessary for HEV neogenesis and the 
corollary infiltration of naïve T-cells into established melanoma tumors in pre-clinical models of 
melanoma 245. Using WT, TNF-/- and TNFR1/2-/- mice, the authors demonstrated that only tumors 
grown in TNFR1/2 -/- hosts had significantly decreased expression of PNAd+ HEVs and infiltration 
of CD62L+ naïve lymphocytes 245. Since HEV density and naïve lymphocyte infiltration was 
comparable in TNF-/- hosts as compared to WT control animals, the authors postulated that the 
agonistic interaction of the alternative TNFR ligand, LTα3, and host TNFR1/2 was responsible for 
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HEV/TLS neogenesis. Accordingly, the adoptive transfer of either TNF-/- or LTA-/- CD8+ T-cells 
into Rag-/- hosts revealed that HEV/TLS formation was negatively affected only in the cohort that 
received LTA -/- CD8+ T-cells 245. Finally, using WT -> TNFR1/2-/- and reciprocal bone marrow 
chimera experiments, it was shown that TNFR1/2 expression on host (endothelial) cells and its 
activation by LTα3 produced by endogenous/transferred TILs was ultimately necessary for 
successful HEV/TLS neogenesis in the setting of melanoma 245 and sarcoma 236. 
These findings suggest that treatments inducing production of LTα in the hematopoietic 
compartment and/or the administration of agonistic antibodies targeting TNFR1/2 within the TME 
may favor conditional formation of tumor associated HEVs and TLS. 
1.3.3.2.5.4 Ectopic expression of IL-36 
We have previously shown that local overexpression of IL-1F9/IL-36γ within the TME induces 
local TLS formation. In untreated human colorectal cancer, IL-36γ is expressed by the tumor 
vasculature, and this expression correlated with an increase in the density of CD20+ B-cells within 
TLS in tumors, indicating that local IL-36γ production may also play a role in maintaining TLS 
262. In pre-clinical studies, Chen et al. demonstrated that DCs engineered to overexpress Tbet (i.e., 
DC.Tbet) were particularly effective in sponsoring TLS development upon direct injection into 
tumor lesions 237. This effect was strictly dependent on the production of IL-36γ (known to be 
transactivated by Tbet) by DC.Tbet cells, as both the therapeutic benefit and TLS formation were 
lost in IL-36R−/− mice receiving DC.Tbet treatment. Further experiments with DCs engineered to 
overexpress IL-36γ suggested that DC. IL36γ concomitantly upregulated the expression of Tbet, 
highlighting an operational positive feedback loop between IL-36γ and Tbet associated with the 
ability of these genetically modified DCs to induce TLS in a transplantable mouse model of colon 
cancer 237. Several factors that are involved in TLS formation, including but not limited to LTα, 
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IFNγ, Tbet, CXCL9, and CXCL10, are upregulated by autocrine/paracrine activation of the IL-
36R expressed by immune and stromal cells within the TME 263. 
1.3.3.2.5.5 Homeostatic chemokines and HEV/TLS formation in the TME 
Following the development of specialized vasculature, homeostatic chemokines play an 
important role in recruiting and organizing interactions between lymphocytes and APCs. In this 
context, ectopic expression of homeostatic chemokines has also been explored as a strategy to 
induce TLS formation. 
CXCL13 
The forced expression of B-lymphocyte chemoattractant (BLC)/CXCL13 under the influence 
of the rat insulin promoter (RIP) in β cells of the pancreas induced the formation of TLS containing 
B-cells, T-cells and MAdCAM1+/PNAd+ HEVs with a further elevated production of BLC in 
tissue immediately surrounding the observed follicles 248. These changes were indeed dependent 
on the initial infiltration of B-cells and the activation of the LTαβ-LTβR signaling cascade in the 
pancreas 248. In cancer, the local production of CXCL13 by TFH 264 and tumor-associated 
fibroblasts 256 correlated positively with the presence of GCs containing CXCR5+ B-cells 
suggesting that ectopic expression of CXCL13 could independently drive TLS neogenesis. 
CCL19 and CCL21 
Additionally, the overexpression of CCL19 and CCL21 may also induce TLS neogenesis by 
recruiting CCR7+ naïve T/B-cells and APCs. In murine studies, Luther et al. demonstrated that the 
ectopic expression of CCL19 (RIP-CCL19) or CCL21 (RIP-CCL21) in murine pancreatic tissue 
sponsored the formation of TLS containing CD4+ T-cells, B220+ B-cells and CD11c+ DCs 
surrounding HEVs 265. In both instances, TLS formation was strictly dependent on the chemokine 
induced expression of LTα1β2, IL-4 and IL-7 by CD4+ T-cells 265. Further, the ectopic expression 
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of CCL21 in the thyroid gland (TGCCL21) also induced CD3+ B220+ TLS neogenesis which 
required, both, endogenous CD4+ T-cells and local LTβR activation 266.  
1.3.3.2.6 Prognostic value of HEVs and TLS in solid cancers 
In this regard, supporting SLO reactions with immune priming in TLS may confer several 
therapeutic benefits. Firstly, canonical TLS, which typically form at the tumor margin (i.e., the 
interface between tumor and normal adjacent tissue), are thought to improve antitumor immune 
responses by facilitating T-cell activation proximal to sites of (neo)antigen load and active disease, 
thus limiting the inefficiencies associated with DC migration, distal T-cell induction and 
subsequent recruitment into the TME 240 267. Secondly, the tumor stroma contains a high antigen 
load in addition to bearing rich APC infiltration, making it an attractive auxiliary site for the de 
novo priming of T and/or B-cells 268. Lastly, TLS may also serve as a haven for immune activation 
and/or function. In human melanoma patients who received ICB treatments, TLS associated T-
cells expressed greater levels of activation and co-stimulatory markers including CD25, CD44 and 
4-1BB respectively when compared to disperse T-cell infiltrates 232. Furthermore, TLS-associated 
B-cells also expressed elevated levels of Ki67 compared to non-TLS B-cell infiltrates which 
together suggests that TLS augment B- and T-cell functionality within the TME 232. Weinstein et 
al. observed similar trends in murine models of colon cancer where TIL isolated from mice treated 
with therapeutic HEV/TLS-inducing DC.IL-36 vaccines also collectively expressed lower levels 
of T-cell exhaustion markers CTLA-4, PD-L1 and Tim-3 237.  
Therefore, TLS, by virtue of approximating T and/or B-cells with stimulatory APCs in an 
antigen-rich environment, may promote superior (cross)priming and functionality of T and B-cells 
exhibiting unique, locally expanded (anti-tumor) repertoires. 
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1.3.4 STING agonists as anti-angiogenic agents 
Given the phenotypic abnormality of tumor vessels and the requirement of functional blood 
vessels for successful T-cell access to the tumor, angiostatic agents hold significant therapeutic 
value in treating cancer by way of slowing angiogenesis to fortify dysfunctional tumor vasculature 
leading to enhanced T cell infiltration and the corollary local inflammation that ultimately facilitate 
tumor clearance. In this regard, recent cancer studies exploring the therapeutic relevance of small 
molecule agonists of the Stimulator of Interferon Genes (STING) suggest that intratumoral STING 
activation might be highly anti-angiogenic. 
Although traditionally known for its role in virus detection, STING has recently garnered 
attention as a candidate immune adjuvant in the treatment of cancer thanks to its robust ability to 
drive type I immunity upon conditional activation. However, pre-clinical dose-escalation studies 
for STING agonists in cancer revealed that therapeutic failure at high, near-MTD doses of several 
STING agonists (5,6-dimethylxanthenone-4-acetic acid (DMXAA) and 10-carboxymethyl-9-
acridanone (CMA)) was associated with overt apoptosis of both tumor blood vessels 269  and tumor 
infiltrating T-cells 270 271  resulting in an immunologically-cold, pro-tumoral TME. Therefore, 
given STING’s potent angiostatic function, and in line with previously published vascular 
paradigms, STING agonists, when dosed appropriately, may be expected to have novel utility as 
vascular and immune reconditioning agents capable of enhancing the T-cell dependent 
surveillance of cancer.  
The following section introduces a few fundamental concepts in STING biology and is followed 
by a section that presents mechanistic evidence for STING’s proposed role in reconditioning the 
TME for improved immune cell delivery and therapeutic function. 
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1.3.4.1 What is STING? 
STING (also known as N-Terminal Methionine-Proline-Tyrosine-Serine Plasma Membrane 
Tetraspanner (MYPS), Transmembrane Protein 173 (TMEM173)) is an intracellular ER-
associated pattern recognition receptor which serves to detect cytosolic dsDNA in eukaryotes 272. 
In mammals, the detection of cytosolic DNA is a multi-step process that involves several accessory 
proteins both upstream and downstream of STING. Interestingly, STING does not directly 
recognize dsDNA but rather recognizes cGAMP, the catalyzed dsDNA product released by the 
cytosolic enzyme cyclic GMP AMP synthase or cGAS 273. Although the role of STING in viral 
surveillance has been well studied 274 275, evidence of free-floating circulating tumor DNA 
(ctDNA) 276 277 and tumor-derived cGAMP 278 within the TME has focused significant attention 
on the role of STING in therapeutic anti-tumor responses. Furthermore, STING activation might 
also logically extend therapeutic benefits in the cancer setting given that it enhances production of 
a number of inflammatory cytokines including, but not limited to, IFN-I which has previously 
exhibited independent therapeutic value in clinical trials 279. STING therefore represents a relevant 
and attractive therapeutic target in the TME and the interest surrounding its role in cancer is 
evidenced by the emergence of several small-molecule agonists being tested in early phase clinical 
trials as outlined in Table 3.  
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Table 3: STING agonists currently being investigated in clinical trials 
 
1.3.4.2 The STING signaling cascade 
The STING signaling cascade is a well-regulated, multi-step process. First, STING activation 
by cGAMP leads to a series of conformational changes, both, within the STING molecule and in 
independent accessory proteins which interact with STING, that ultimately transduce downstream 
signals. The first step in STING activation involves the binding of cGAMP/synthetic CDNs to the 
pocket-like STING ligand binding domain 280. While human STING ligand binding domain 
resembles an open binding pocket, murine STING ligand binding domain adopts a more closed 
configuration, and this critical interspecies difference underscored the early clinical challenges 
faced by flavonoid STING agonists like DMXAA, whose spatial properties could only activate 
smaller murine STING ligand binding domain 281-284. These findings have led to the careful 
development of subsequent STING agonists which possess an ability to bind both, murine and 
human STING ligand binding domain, and several such multispecies STING agonists are listed in 
Table 3. Regardless, following successful activation, the STING ligand binding domain undergoes 




Cancer Type Route  Combination Phase/Status Phase Identifier 
1a E7766 Urinary bladder 
neoplasm 
intravesical N/A Recruiting I NCT04109092 
1b “ Lymphoma or 
advanced solid tumors 
intratumor N/A Recruiting  I NCT04144140 
2 GSK3745417 Neoplasm intravenous Pembrolizumab Recruiting  I NCT03843359 
3a ADU S-100 Solid tumors or 
lymphomas 
intratumor PDR001 Active not 
recruiting 
I NCT03172936 
3b “ Advanced metastatic 
or solid tumors or 
lymphomas 
intratumor Ipilimumab Active not 
recruiting 
I NCT02675439 
3c “ Metastatic HNSCC intratumor N/A Recruiting  II NCT03937141 
4 SNX281 Advanced solid 
tumors or lymphomas 
intravenous Pembrolizumab Recruiting  I NCT04609579 
5 TAK-676 Solid neoplasms intravenous Pembrolizumab Recruiting  I NCT04420884 
6 SB11285 Melanoma or HNSCC 
or other solid tumors 
intravenous Atezolizumab Recruiting I NCT04096638 
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induces a conformational change to the STING C terminal tail (CTT) 286 287. Together, these two 
conformational changes allow STING to interact with its accessory downstream kinase, Tank 
Binding Kinase 1 (TBK1) 288. TBK1 crucially licenses STING to interact with associated 
transcription factors, especially IRF3, by phosphorylating a conserved PLxIS domain on STING’s 
CTT to create negatively charged moieties capable of attracting positively charged domains of 
IRF3 289. While STING does not possess any intrinsic kinase activity, it plays a pivotal role in this 
process by functioning as a scaffold protein to approximate TBK1 and IRF3 interactions for 
subsequent phosphorylation events. Remarkably, proteomic sequencing revealed that IRF3 also 
contains a PLxIS domain which serves as a second substrate for the kinase activity of TBK1 290. 
Phosphorylated IRF3 subsequently detaches from the STING CTT and dimerizes with a second 
pIRF3 monomer before translocating to the nucleus, where this homodimer induces the expression 





Figure 3: The canonical STING signaling cascade 
Graphical representation of the stepwise activation of the STING signaling cascade involving 
downstream phosphorylation of TBK1 and IRF3. *Shapes depicted are not representative of 
actual protein 3D structure. 
1.3.4.3 Dose-dependent characteristics of STING agonists – clues for the 
vasculature/immune normalization in the TME 
Interestingly, although well-tolerated, dosing studies with STING agonists suggest that 
immune-dependent, durable anti-tumor responses to these agents are observed only at doses well 
below the maximum tolerable dose (MTD). Specifically, previous reports using first generation 
STING agonists (DMXAA and CMA) have elegantly demonstrated, i.e., cautioned, that the use of 
high, near-MTD doses of STING agonism yields poor immune protection in part by strongly 
inducing apoptosis in tumor infiltrating T-cells 270 271. Separately, other flavonoid-based STING 
agonists (such as DMXAA) when administered at high, near MTD-doses also promote the 
selective ablation of tumor endothelial cells (i.e., vascular necrosis), but not endothelial cells of 
other peripheral organs, which, besides disrupting important physiological functions, may also 
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directly limit immune cell delivery into the TME 269 (Fig. 4). In contrast, recent studies using 
metronomic, sub-MTD dosing of STING agonists show profound tumor protection, wherein the 
therapeutic TME is characterized by enhanced infiltration of TILs with no observable T-cell 
toxicities 296 (Fig. 4). However, while such studies have shown remarkable success in slowing 
tumor growth with sub-MTD doses of STING agonists, they have stopped short of characterizing 
therapy-associated changes to the tumor vasculature which we expect will evolve on-treatment 
given STING’s documented ability to modulate tumor angiogenesis.  
 
Figure 4: Dose-dependent effect of STING agonism in the treatment of cancer.  
High, near-MTD doses of STING agonist leads to the necrosis and acute ulceration of tumor tissue, 
apoptosis of infiltrating immune cells, especially effector T-cells, and ablation of tumor endothelial 
cells. Contrastingly, sub-MTD metronomic dosing of STING agonists promotes T-cell infiltration 
into the TME and inhibits tumor growth via apoptosis without operational vasoablation.  
1.4 Statement of the problem 
T-cells constitute a critical arm of the adaptive immune system that are responsible for 
mediating effective immunosurveillance and eradicating rapidly evolving cancers. However, 
cancer cells counter T-cell mediated tumor rejection by developing abnormal vascular networks 
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(via rapid angiogenesis) that effectively exclude T-cells from the TME. The pathologic growth of 
solid tumors is therefore often characterized by an immune cell- and inflammation-devoid, ‘cold’ 
TME. Thus, a key challenge facing the optimization of cancer immunotherapy approaches lies in 
appropriately conditioning the TME for enhanced recruitment of tumor-reactive T-cells capable 
of rejecting solid tumors. In this regard, appropriate dosing of anti-angiogenic therapies has been 
shown to therapeutically counteract the highly-angiogenic TME, leading to normalized tumor 
blood vessels that support improved T-cell infiltration into the tumors. 
Early studies characterizing STING agonists have demonstrated their potent ability to ablate 
tumor vascular networks highlighting their anti-angiogenic potential within the TME.  In this 
regard, pre-clinical studies have now shown that while tumor rejection at high, near-MTD doses 
of STING activation is associated with an immune-independent, vaso-ablative response, 
therapeutic tumor rejection at sub-MTD doses is characterized by a robust intratumoral infiltration 
of anti-tumor T-cells. However, whether this enhanced T-cell infiltration at sub-MTD doses is 
linked to therapeutic changes to the tumor vasculature remains underappreciated. Unraveling these 
vascular-centric therapeutic underpinnings for the anti-tumor activity of low-dose STING agonism 
will inform the development of more effective next-generation STING agonists-based 
immunotherapies for solid cancers. 
1.5 Hypothesis 
In line with previously proposed VN paradigms, I hypothesize that provision of sub-MTD, low-
doses of STING agonist within the TME will achieve optimal T-cell infiltration by refurbishing 
and/or reprogramming the tumor vasculature (i.e., vascular normalization or VN), leading to a 
state of sustained cell- and cytokine-mediated type I inflammation capable of sponsoring 
HEV/TLS induction which together result in the “immune normalization” of the melanoma TME. 
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Indeed, the original research detailed in the following chapter of this thesis successfully 
identifies normalization of existing tumor vasculature and neovascularization of HEVs as two 
therapeutic vascular mechanisms through which sub-MTD doses of STING agonism potentiate T-
cell infiltration and local HEV-related TLS formation in treated melanomas. 
Briefly, I demonstrate that the therapy-associated response to sub-MTD doses of STING 
agonist ADU S-100 promotes robust infiltration of therapeutic T-cells into the TME by 
normalizing the existing tumor vasculature, inducing HEV formation, and ultimately the formation 
of non-classical TLS within the melanoma TME. Supporting the putative functions of normalized 
vessels and HEVs/TLS, we also observed quantitative and qualitative differences in the treatment-
associated T-cell repertoire, as STING-treated tumors contained both increased numbers of 
peripherally expanded T-cell clonotypes (as a function of VN) and a unique TIL repertoire of CD8+ 
T-cells expanded locally within the TME (in association with HEV/TLS neogenesis).  
These findings suggest that the enhanced therapeutic T-cell response observed with low-dose 
STING agonism relies on therapeutic changes to the tumor vasculature which facilitate enhanced 
accumulation of tumor-reactive T-cells that are either recruited from the circulation after initial 
cross-priming in the periphery or that are recruited as naïve T-cells and locally cross-primed within 
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2.1 Chapter synopsis 
 
Background: The degree of immune infiltration in tumors, especially CD8+ T cells, greatly impacts 
patient disease course and response to interventional immunotherapy. Enhancement of TIL is a critical 
element of efficacious therapy and one that may be achieved via administration of agents that promote 
tumor vascular normalization (VN) and induce the development of tertiary lymphoid structures (TLS) 
within the tumor microenvironment (TME).  
Methods: Low-dose STING agonist ADU S-100 (5 μg/mouse) was delivered intratumorally to 
established s.c. B16.F10 melanomas on days 10, 14 and 17 post-tumor inoculation. Treated and control 
tumors were isolated at various time points to assess transcriptional changes associated with VN and 
TLS formation via qPCR, with corollary immune cell composition changes in isolated tissues 
determined using flow cytometry and immunofluorescence microscopy. In vitro assays were performed 
on CD11c+ BMDCs treated with 2.5 μg/mL ADU S-100 or CD11c+ DCs isolated from tumor digests 
and associated transcriptional changes analyzed via qPCR or profiled using DNA microarrays. For 
TCRβ-CDR3 analyses, T cell CDR3 was sequenced from gDNA isolated from splenocytes and 
enzymatically digested tumors.  
Results: We report that activation of STING within the TME leads to slowed melanoma growth in 
association with increased production of anti-angiogenic factors including Tnfsf15 (Vegi) and Cxcl10, 
and TLS-inducing factors including Ccl19, Ccl21, Lta, Ltb and Light. Therapeutic responses resulting 
from intratumoral STING activation were characterized by improved VN, enhanced tumor infiltration 
by CD8+ T cells and CD11c+ DCs and local TLS neogenesis, all of which were dependent on host 
expression of STING. Consistent with a central role for DC in TLS formation, ADU S-100-activated 
mCD11c+ DCs also exhibited upregulated expression of TLS promoting factors including 
lymphotoxin-α (LTA), IL-36, inflammatory chemokines and type I interferons in vitro and in vivo. TLS 
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formation in ADU S-100-treated mice was associated with the development of a highly oligoclonal 
TIL repertoire enriched in expanded T cell clonotypes unique to the TME and not detected in the 
periphery. 
Conclusions: Our data support the premise that i.t. delivery of low-dose STING agonist promotes VN 
and a pro-inflammatory TME supportive of TLS formation, enrichment in the TIL repertoire and tumor 
growth control. 
2.2 Background 
Melanoma remains a significant health concern, representing the 5th most commonly diagnosed 
form of cancer in the US in 20201. Many melanoma patients lack discernable tumor infiltrating 
lymphocytes (TIL), a harbinger of poor clinical prognosis and responsiveness to first-line immune 
checkpoint blockade160. This places a premium on development of interventional regimens that 
effectively promote a pro-inflammatory TME, which may then be combined with immune 
reinvigorating therapies such as checkpoint blockade to optimize objective clinical response rates 
amongst advanced stage melanoma patients with primary/acquired resistance to first-line intervention. 
In this context, we and others have actively studied therapeutic VN as an interventional strategy to 
promote enhanced immune infiltration and a pro-inflammatory TME 205 297. In the VN paradigm 
originally proposed by Jain et al.176 298, provision of anti-angiogenic agents at low-moderate (sub-MTD) 
doses results in improved tumor vascular integrity and perfusion, leading to tissue normoxia, increased 
stromal production of pro-inflammatory chemokines and augmentation in levels of TIL298 299. One class 
of agents that concomitantly activates robust inflammatory immune responses includes agonists of 
STING, a cytosolic dsDNA sensor, which have demonstrated therapeutic potential in early phase 
clinical trials300,301. However, the mechanisms underlying effective treatment of cancer with STING 
agonists remain only partially resolved.   
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We now report that intralesional treatment of melanoma-bearing mice with STING agonist ADU S-
100 promotes local production of anti-angiogenic factors and normalization of tumor associated 
vasculature. Additionally, local STING activation also upregulates the production of TLS-inducing 
chemokines/cytokines within the TME and the maturation of dendritic cells (DC) supporting increased 
pro-inflammatory immune infiltration and formation of non-classical TLS in association with 
controlled tumor growth. These therapeutic effects are strictly dependent on host, but not tumor cell, 
expression of STING. Furthermore, the STING therapy associated TIL TCR repertoire demonstrates 
greater clonality and population richness vs. TIL in control mice. This includes an expanded cohort of 
unique T cell clonotypes found only in the TME, supporting the concept of local cross-priming of T 
cells within the therapeutic TME. 
Together, these findings further our translational understanding of STING agonist-based treatment 
regimens in the cancer setting and support a paradigm for VN and local TLS formation in the 
operational effectiveness of this class of immunotherapeutic agent.   
2.3 Methods 
2.3.1 Animal models and cell culture 
Female C57BL/6J (Cat. No. 000664), STINGKO goldenticket (Cat. No. 017537) and BALB/C 
(Cat. No. 000651) mice aged between 6-8 weeks were purchased from Jackson Laboratory (Bar 
Harbor, ME). All mice were housed in a pathogen-free facility at the University of Pittsburgh and 
handled according to protocols approved by the Institutional Animal Care and Use Committee 
(IACUC). The B16.F10 (CRL-6475) and RENCA (CRL-2947) murine tumor cell lines were 
purchased from ATCC (Manassas, VA), maintained and passaged under sterile conditions. 
B16.F10 and RENCA cells were cultured in RPMI (Cat. No. 21870-076, Gibco) supplemented 
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with 10% heat-inactivated fetal bovine serum (Cat. No. F442, Sigma-Aldrich, St. Louis, MO), 100 
μg/mL streptomycin, 100U/mL penicillin (Cat. No. 15140-22, Gibco) and 10 mmol/L L-glutamine 
(Cat. No. 25030-081, Gibco) in a humidified incubator under 5% CO2 tension and 37oC. BPR20 
(BRAFV600EPTEN-/-) melanoma cells were derived from the BP melanoma cell line302(the kind gift 
of Dr. Jennifer Wargo, MD Anderson Cancer Center) under in vitro selection with 20 M 
Dabrafenib in complete DMEM culture media. All cell lines were tested for, and confirmed to be 
free of, mycoplasma contamination. 
2.3.2 Animal experiments  
Mice received subcutaneous (s.c.) injections of 105 syngeneic B16.F10, BPR or RENCA tumor 
cells in 100 μL of PBS on the right flank (or in both flanks for bilateral model experiments). Ten 
days after inoculation, tumors were measured, and mice were randomized to obtain cohorts with 
comparable mean tumor sizes. Mice were then injected intratumorally (right flank) with sterile 
PBS or 5 μg of endotoxin free ADU S-100 (Cat.No: HY-12885B, MedChemExpress) resuspended 
in sterile PBS. Repeat injections were administered on days 14 and 17 post-tumor inoculation. 
Tumor growth was monitored daily and measured (two dimensions; long axis and short axis) every 
two days using a Vernier caliper. Tumor growth is reported as tumor area (in mm2 + SD) based on 
the product of orthogonal measurements of the long and short axes of the palpable tumor. For 
studies characterizing the tumor vasculature, mice received an i.v. injection of 200 μL of 1 mg/mL 
of Alexa Fluor 488-conjugated Lycopersicon Esculentum (a.k.a. lectin) (Cat. No. DL-1174-1, 
Vector Laboratories) diluted in sterile PBS just prior to euthanasia. All mice were monitored, 
treated and euthanized according to IACUC approved protocols and the University of Pittsburgh’s 
Division of Laboratory Animal Resources (DLAR) recommended guidelines. 
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2.3.3 Bone marrow harvest and dendritic cell culture 
Bone marrow (BM) isolated from C57BL/6J mice was treated with ACK lysis buffer to remove 
contaminating RBCs. Purified bone marrow cells were plated in a 6-well plate at a density of 2 x 
106 cells/5 mL of DC culture media (complete RPMI + rmGM-CSF (1000U/mL, Peprotech) + 
rmIL-4 (1000U/mL, Peprotech)) in a humidified incubator at 37oC and 5% CO2. BM culture was 
supplemented with fresh DC culture media on day 3, with cells harvested by scraping on day 5. 
CD11c+ DC were isolated using STEMCELL magnetic CD11c+ negative selection kits per the 
manufacturer’s protocol. For in vitro experiments, 2.5 μg/mL of ADU S-100 was added to CD11c+ 
DCs in culture for 16h at 37oC. For TBK1 inhibition experiments, CD11c+ DCs were pre-treated 
with 150 μg/mL Amlexanox (InvivoGen) for 1h at 37oC, prior to addition of 2.5 μg/mL of ADU 
S-100. 
2.3.4 Western blotting  
Cells for western blotting were collected and washed twice using cold PBS. Cell pellets were 
lysed using a lysis buffer containing protease inhibitor cOmplete Mini (Cat. No. 11836170001, 
Roche) and phosphatase inhibitor, phosSTOP (Cat. No. 4906837001, Roche) and incubated at 4oC 
for 30 minutes. Protein containing supernatants were isolated following high-speed centrifugation 
at 4oC. Purified proteins were boiled and separated on SDS PAGE gels in reducing conditions. 
Post separation, the proteins were blotted on to PVDF membranes, blocked using 5% non-fat dry 
milk in PBS + 0.1% Tween-20 or 5% BSA solution in TBS + 0.1% Tween-20 for 1 hour at RT. 
Appropriate primary antibodies (listed in Table 4) in 2% NFDM in PBST or in 2% BSA in TBST 
were incubated for 16-18h at 4oC. Appropriate HRP conjugated secondary antibodies (1:10000 in 
2% NFDM) were incubated for 1 hour at room temperature. SuperSignal West Femto (Cat. No: 
34095, Thermo) chemiluminescence substrate was used to visualize resulting protein bands. 
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2.3.5 Tumor tissue processing  
Tumors were resected on the day of euthanasia and were digested using a cocktail of enzymes 
[RPMI containing DNAse I (Sigma D5025 @ 20U/mL), Collagenase IA (Sigma C5894 @ 0.5 
mg/mL), Collagenase II (C1764 @ 0.5 mg/mL) and Collagenase IV (Sigma C1889 @ 0.5 mg/mL)] 
for 30 minutes at 37oC on a shaker. Tumor digests were then dissociated through a 70 μm filter 
and washed twice using PBS. Tumor-derived single cell suspensions were then analyzed.  
2.3.6 Flow cytometry  
Purified cell populations and tumor digests were washed twice with PBS prior to flow staining. 
Tumor digests were blocked with FcR block (BD Pharmingen, Cat. No: 553142) prior to staining 
for flow cytometry. Cells were then incubated with appropriate primary antibodies in FACS buffer 
for 30 minutes at 4oC prior to flow cytometry analysis performed using either BD LSR II or BD 
Fortessa machines within the Unified Flow Cytometry Core at the University of Pittsburgh. Flow 
cytometry data was acquired using BD FACSDiva software and analyzed using FlowJo version 
10. 
2.3.7 Immunofluorescence microscopy  
Tumor tissues were processed and stained using protocols published by the University of 
Pittsburgh’s Center for Biological Imaging (CBI, https://www.cbi.pitt.edu). Probes used are listed 
in Table S1. Fluorescence images were acquired using Olympus Provis or Nikon 90i microscopes. 
Quantitation of fluorescent probes were performed on the Nikon Elements AR or ImageJ software. 
Post-acquisition statistical analyses on fluorescent images were performed on GraphPad Prism 8. 
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2.3.8 Real Time PCR  
mRNA from CD11c+ DCs or enzymatically dissociated tumors was isolated using the RNEasy 
Micro Plus Kit (Cat. No. 74034, Qiagen) according to manufacturer’s protocol. Isolated mRNA 
was converted to cDNA using a high-capacity RNA to cDNA kit (Cat. No. 4387406, Applied 
Biosystems). Quantitative PCR was performed on cDNA using the Fast SYBR Green Master Mix 
(Cat. No. 4385612, Applied Biosystems). PCR reactions were quantitated on the StepOnePlus 
thermocycler (Applied Biosystems). Gene expression was normalized to mHPRT1 (Cat. No. 
QT00166768, Qiagen) and fold changes were calculated using 2-ΔΔCt method. Primer sequences 
are listed in Table 5. 
2.3.9 Tumor apoptosis assay  
Cultured B16.F10 cells were treated with PBS or 2.5 μg/mL of ADU S-100 for 30 hours or 0.5 
μM staurosporine (Cat. No: S1421, Selleckchem) for 5 hours. Following incubation with 
respective drugs, tumor cells were harvested by trypsinization. Induction of apoptosis was 
quantified using flow cytometric analysis of Annexin V (Cat. No: V13246, Invitrogen) and 
LIVE/DEAD Fixable Aqua staining (Cat. No: L34957, Invitrogen). 
2.3.10 TCRβ-CDR3 sequencing  
gDNA was isolated from day 18 tumor digests (processed as detailed above) and spleen digests 
(mechanically disrupted, ACK lysed). Following gDNA isolation, TCRβ CDR3 gene regions were 
amplified using proprietary primers designed by Adaptive Biotechnologies (Seattle, WA). 
Amplified TCRβ-CDR3 regions were then sequenced at a survey depth using the Illumina HiSeq 
platform. gDNA isolation, CDR3 library preparation and CDR3 sequencing were all performed on 
a fee-per-service basis by Adaptive Biotechnologies. Analysis of TCR sequencing data was 
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performed using the ImmunoSEQ Analyzer, a proprietary TCRseq analysis software created by 
Adaptive Biotechnologies. 
2.3.11 Statistical tests  
Comparisons between two groups were performed using two-tailed Student’s t-tests while 
comparisons between multiple groups were performed using (one-way or two-way) analysis of 
variance (ANOVA) with Tukey’s post-hoc analysis. p-values < 0.05 were considered significant. 
Prism 8 (GraphPad Software Inc., La Jolla, CA) was used to generate graphs and perform statistical 
tests. 
2.4  Results 
2.4.1 STING agonist ADU S-100 slows tumor growth, promotes VN and enhances 
immune cell infiltration into the TME 
Previous reports have highlighted the immune-independent tumor rejection and dose-dependent 
toxicities of STING agonist-based therapy296 303 304. To mitigate such adverse effects, we evaluated the 
anti-tumor potential of STING activation in the TME by administering low-doses of the small-molecule 
STING agonist ADU S-100 intratumorally (i.t.) in transplantable subcutaneous (s.c.) murine B16.F10 
melanoma models.  In order to avoid vasoablation and T cell apoptosis observed with high, near-MTD 
doses of STING agonists270 305 306, and based on preliminary findings for tumor ulceration necessitating 
euthanasia at doses > 5 μg/tumor (data not shown), we adopted the use of a low-dose (5 μg/tumor; i.e. 
~100-fold lower than conventional dosing) of ADU S-100 for i.t. injections administered on days 10, 
14 and 17 post-tumor inoculation (Fig. 5A). Under these treatment conditions, ADU S-100 injections 
resulted in slowed tumor growth (Fig. 5B) and prolonged survival (Fig. 5C) vs. mice treated with PBS. 
Similar anti-tumor effects for this interventional therapy were observed in two unrelated s.c. tumor 
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models; BPR (BRAFV600EPTEN-/-) melanoma in C57BL/6 hosts (Fig. 6a) and RENCA renal carcinoma 
in BALB/c hosts (Fig. 6b).  
Since the first-generation murine STING agonist, DMXAA, was developed as an anti-angiogenic 
agent304, we sought to determine whether delivery of low-dose ADU S-100 would support VN via a 
paradigm originally proposed by Jain et al.6, leading to increased production of anti-angiogenic factors 
within the treated TME. To test this hypothesis, RNA was isolated from PBS control- or ADU S-100-
treated tumors and analyzed by qPCR for expression of anti-angiogenic factors307 308.  Compared to 
control tumors, ADU S-100 treated tumors coordinately expressed: i.) significantly elevated levels of 
transcripts encoding anti-angiogenic factors Tnfsf15 (Vegi) and Cxcl10, and ii.) significantly reduced 
expression of hypoxia-associated transcripts Hif1a and Hif2a (Fig 5D) and hypoxia-responsive cancer 
stem cell markers CD133 and Jarid1b204 (Fig 5E), which together supported possible VN in the TME 




Figure 5: Intratumoral STING activation slows melanoma growth in mice.  
A. Schematic depiction of our in vivo experimental design. C57BL/6J mice bearing 
subcutaneous B16.F10 tumors received three intratumoral injections of 5µg ADU S-100 over the 
span of a week. (n=5/group) B. representative tumor growth curves from cohorts of B16.F10 
melanoma showing significantly slower tumor growth kinetics when mice were treated with ADU 
S-100 intratumorally. Tumor measurements represented as total tumor area (calculated as small 
axis X large axis) ****p < 0.0001, two-way ANOVA C. Representative Kaplan-Meier survival plot 
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depicting improved survival in mice treated with ADU S-100 vs control mice. *p = 0.005, 
MantelCox log RANK test. D. Post-treatment tumor digests obtained on day 18 show 
transcriptional signatures associated with vascular normalization such as with increased anti-
angiogenic factors (Tnfsf15/Vegi, Cxcl10) and decreased tissue hypoxia (using Hif1a and Hif2a 
as biomarkers) in ADU S-100 treated tumors. *p < 0.05; **p < 0.002. E. Immunofluorescence 
staining and image quantitation showing reduced expression of hypoxia-responsive cancer stem 
cell markers CD133 and JARID1B in ADU S-100-treated B16.F10. *p< 0.05; ***p < 0.0002. 




Figure 6: STING agonist ADU S-100 slows growth of BPR Melanoma and RENCA renal cell 
carcinomas in syngeneic immunocompetent hosts. 
Representative tumor growth curves from treated cohorts (n = 5/group) of C57BL/6 mice bearing 
established BPR melanomas (A) or BALB/c mice bearing established RENCA renal cell 
carcinomas (B) as described in Fig. 5 and Materials and Methods. Note significantly slower tumor 
growth kinetics when mice were treated with STING agonist ADU S-100 intratumorally. Tumors 
were measured using calipers and sizes are represented as total tumor area (calculated as small 
axis x large axis). *p < 0.05, Two-Way ANOVA. Representative tumor growth curves from three 
independent experiments. 
 
We next performed immunofluorescence microscopy (IFM) studies on isolated tumor sections from 
control vs. ADU S-100-treated mice to discern therapy impact on indices of VN including vessel 
perfusion and tight pericyte coverage of blood vessels. Analysis of tumor specimens isolated from mice 
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tumors from mice treated with ADU S-100 displayed improved perfusion vs. tumors isolated from 
PBS-treated control mice (Fig. 7A-B). Furthermore, IFM analyses confirmed improved PDGFRβ+ 
pericyte coverage of CD31+ VECs in ADU S-100 treated vs. control B16 tumors (Fig. 7C-D, Fig. 8) 
with the tight approximation of the CD31- and PDGFRβ-associated fluorescence signals on the 
abluminal vascular surface, consistent with the ability of low-dose ADU S-100 to promote therapeutic 
VN 298 309.  We also observed that CD31+ VECs in tumors treated with ADU S-100 exhibited increased 
expression of VCAM1, an endothelial cell marker known to be upregulated in response to improved 
oxygenation310 and inflammation187 188, and which facilitates tissue recruitment of circulating VLA-4+ 
T effector cells (Fig. 7G-H).  
Another specialized vasculature in the TME is the lymphatic endothelial network. Lymphatics serve 
as draining conduits to lymph nodes (LN), permitting transport of APCs for adaptive immune cell 
priming in conventional secondary LNs311. Lymphatic vessels drain interstitial fluid from the TME, 
thus reducing tumor interstitial fluid pressure (TIFP) and facilitating influx of immune cell populations 
from the circulation176 312. Therapeutic lowering of TIFP in the TME via enhanced development of 
lymphatic vessels represents an additional index of VN176 and has also recently been identified as a 
positive prognostic indicator in human melanoma313. In this regard, murine melanomas treated with 
low-dose STING agonist ADU S-100 exhibited significant increases in the density of Lyve-1+ 
lymphatic endothelial cells (LEC) vs. PBS-treated control tumors (Fig. 7E-F).  
Importantly, the presence of normalized and activated vascular networks in the therapeutic TME 
was associated with robust improvement in tumor infiltration by CD45+ immune cells (Fig. 7I), CD8+ 




Figure 7: Delivery of low-dose STING agonist into the TME promotes vascular normalization 
(VN), lymphangiogenesis and improved immune cell recruitment. 
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A. Representative images of lectin perfused functional vessels in PBS or ADU S-100 treated 
B16.F10 melanoma resected 18 days post-tumor inoculation. B. Quantitation of vessel perfusion in 
PBS or ADU S-100 treated tumors shown as a function of percent CD31+ VECs containing luminal 
lectin-AF488. C. Representative images depicting PDGFRβ+ pericyte coverage on tumor VECs in 
PBS or ADU S-100 treated B16.F10 tumors resected 18 days post inoculation (inset scale 
bar=50µm). D. Quantitation of the percentage of CD31+ VECs with tightly-approximated 
(covering) PDGFRβ+ pericytes based on overlapping fluorescence signals at the abluminal VEC 
surface-pericyte interface. E. Representative images showing increased abundance of Lyve-1+ 
lymphatic endothelial cells in ADU S-100 treated B16.F10 tumors. F. Quantitation of Lyve-1+ LEC 
density per unit area tumor. G. Representative images showing VCAM-1 expression on tumor VECs 
in PBS or ADU S-100 treated B16.F10 melanoma H. quantitation of VCAM-1 expression on CD31+ 
VECs. I. Percent quantitation of live CD45+ cells in resected B16.F10 melanoma treated with PBS 
or ADU S-100. J. Quantitation of CD8+ T cell and CD11c+ DC infiltrates in ADU S-100 treated or 
control B16.F10 tumors. Data are representative of three independent experiments. *p < 0.05; ** p 





Figure 8: Representative high-magnification immunofluorescence image demonstrating separate 
spatial stacking of PDGFRβ+ pericytes and CD31+ VEC in normalized blood vessels found in 
B16 melanomas treated with i.t. ADU S-100. 
Note yellow (overlap of red/green signals) pseudo-coloring of the abluminal VEC cell surfaces 
with tightly approximated pericyte cell surfaces. Scale bar = 100μm 
 
2.4.2 STING-activated CD11c+ DCs develop VN- and TLS-inducing properties 
Having observed an increase in CD11c+ DC infiltration within the ADU S-100 treated TME, and 





immune responses, we next sought to characterize the direct impact of STING agonism on DCs. To 
address this, mCD11c+ BMDCs were treated with PBS or with 2.5 μg/mL ADU S-100 in vitro for 16h, 
after which mRNA expression was profiled using gene chip microarrays. We identified and analyzed 
~1300 annotated gene products that were significantly up/down-regulated in ADU S-100-treated 
CD11c+ DCs [ |log2FC| > 1 and adjusted p-value < 0.05] and observed that their selective expression 
corresponded with several anti-tumor Gene Ontology phenotypes (Fig. 9A, Fig. 10A, Fig. 10B). 
Remarkably, a GSEA on Ingenuity Pathway Analysis (IPA, Qiagen) revealed that ADU S-100-
activated DCs strongly upregulated expression of gene transcripts associated with the inhibition of 
angiogenesis (Fig. 11A) and the organogenesis/development and maintenance of lymphoid tissues 
(Fig. 9B).  
To expand on these findings, we assessed the expression of targets reported in an ad-hoc biomarker 
panel for TLS formation314, in addition to other validated DC-centric, pro-TLS factors including 
lymphotoxins, IL-36β and TNFα237 239 246 315-317.  We observed that STING-activated DCs coordinately 
upregulate several factors within the ad-hoc panel in addition to Lta, Tnfa and Il36b when compared 
to control PBS-treated DCs (Fig. 9C). We validated the gene array expression findings at the 
transcriptional level using qPCR analyses performed on BMDCs treated with ADU S-100 vs. PBS in 
vitro (Fig. 9D) and on CD11c+ DCs isolated from digests of tumors treated with ADU S-100 vs. PBS 
in vivo (Fig. 9E). We further corroborated that the production of these TLS associated factors by DCs 
relied on an IFNAR-independent, but STING-TBK1-IRF3-dependent signaling cascade (Fig. 12).  
Consistent with recent literature linking DC maturation to TLS presence/maintenance in tumors244 
318, microarray findings further suggested that STING activation promotes CD11c+ DC maturation 
(Fig. 9F) leading to the development of a CD54hi+CD86hi+CCR7hi+PD-L1+ mature phenotype 
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confirmed by flow cytometry (Fig. 9G). In sum, our data suggests that STING-activated DCs might 





Figure 9: STING activated DCs exhibit TLS inducing characteristics. 
A. Visualization of Biological Processes Gene Ontology terms associated with differentially 
expressed genes (DEG) in sting activated CD11c+ DCs. Go analysis performed using Partek 
genomics suite, *p < 0.05, one-way ANOVA B. annotated microarray probes cross-referenced 
with ingenuity pathway analysis (Qiagen) implicates Deg gene expression of sting activated DCs 
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in promoting their maturation and in the formation, structure and development of lymphoid tissues. 
C. STING activated DCs upregulate factors associated with TLS formation.20 D. Quantitative 
rtPCR validation of TLS inducing factors highlighted by microarray analysis. E. Quantitative 
rtPCR validation showing increased TLS-associated analyte production by CD11c+ DCs directly 
isolated from digests of tumors treated with ADU S-100 vs PBS in vivo. F. STING activated DCs 
demonstrate a more mature phenotype as evidenced by increased transcript levels of DC 
maturation markers. G. Flow cytometric validation of DC maturation on STING activation. Data 
representative of three independent experiments *p < 0.05; **p < 0.002. ANOVA, analysis of 
variance; DCs, dendritic cells; IFN, interferon TLS; tertiary lymphoid structures.  
 
Figure 10: Transcriptional profiling and pathway analysis of CD11c+ DC treated with ADU S-
100 vs control media. 
A. Biological processes associated with top GO term, immune response (GO:0006955), 
enriched in ADU S-100-treated CD11c+ DCs. *p-value < 0.05, One-way ANOVA. B. Volcano plot 
of CD11c+ DC genes analyzed via microarray. ~1300 genes (shown in purple) were found to be 






Figure 11: STING activation does not improve B220+ B cell recruitment to s.c. B16.F10 
melanomas. 
A. Gene-set enrichment of STING activated CD11c+ DC gene expression showing significant TLS 
nucleating, DC recruiting and T cell recruiting signatures, but poor B cell recruiting signatures. 
Threshold = -log(p-value) of 1.3 or p-value of 0.05. B. Representative immunofluorescence image 
showing no observable differences in B cell infiltration with ADU S-100 vs. PBS treatment of 


















Figure 12: STING activation is sufficient to promote production of TLS factors through a 
STING-TBK1-IRF3 signaling cascade.  
A. Schematic representing canonical STING signaling cascade involving TBK1 and IRF3. B. 
STING activation significantly increases transcript levels of TLS factors in CD11c+ DCs from WT 
hosts which is absent in DCs from STING KO hosts. *p-value < 0.05, One-Way ANOVA. C. 
Inhibition of TBK1 using Amlexanox prior to STING activation ablates production of STING 
associated TLS factors. *p-value < 0.05, One-Way ANOVA. D. Immunoblotting confirms 
upregulation of TLS associated transcripts in CD11c+ DCs (in panel C) occurs only with IRF3 
activation/phosphorylation (S396). E. IFNAR KO DC retain ability to produce TLS factors upon 





















































































































































































































































































































































































































































































































































2.4.3 Treatment with low-dose STING agonist promotes formation of non-classical TLS 
in the therapeutic TME. 
We next investigated whether these STING-driven inflammatory events translated into the 
development of a pro-TLS TME. Tumors harvested on day 18 were analyzed by qPCR for expression 
of homeostatic chemokines and lymphotoxin genes associated with development of secondary/tertiary 
lymphoid tissues230. When compared to control tumors, ADU S-100-treated tumors expressed elevated 
levels of homeostatic chemokines Ccl19 and Ccl21 (but not Cxcl13), and the LTβR agonists Lta, Ltb 
and Tnfsf14/Light (Fig. 13A), suggesting that intratumoral STING activation promotes a TME favoring 
TLS neogenesis. 
To determine whether this treatment regimen resulted in the formation of observable TLS, ADU S-
100 treated B16.F10 tumors were resected at various time points on-treatment, with tumor sections 
analyzed by IFM for the presence of TLS. CD45+ immune clusters surrounding PNAd+ HEVs 
resembling bona-fide TLS319 were identified as early as 5 days after initiating treatment with ADU S-
100 (Fig. 13B). These therapy-induced TLS were richly-infiltrated with CD11c+ DCs and CD3+ T cells, 
resembling previously reported “non-classical” TLS320 (Fig. 13C). IFM analyses did not however 
reveal significant B cell infiltrates in our specimens (Fig. 11B); consistent with our observed lack of 
Cxcl13 expression in the TME of ADU S-100 treated animals (Fig. 13A). TLS were further quantified 
using PNAd+ HEV as a canonical biomarker231 321, revealing that ADU S-100-treated tumors contained 
more HEVs per unit area of tumor vs. control PBS-treated tumor specimens (Fig. 13D). ADU S-100 
treated tumors were also characterized by a marked increase in the number of physical contacts made 
between CD11c+ DCs and CD8+ T cells within the TME (Fig. 13E). Hence, treatment with STING 




Figure 13: Low dose STING activation induces non-classical TLS formation in the therapeutic 
TME.  
A. Post-treatment tumor digests obtained on day 18 show increased transcript levels of TLS 
inducing homeostatic chemokines (Ccl19 and Ccl21) and TLS inducing LTβR agonists (Lta, Ltb 
and Tnfsf14/Light). B. Representative immunofluorescent images showing TLS in ADU S-100 
treated B16.F10 tumors resected on day 15 (2 injections completed) or on day 18 (3 injections 
completed) in comparison to PBS treated B16.F10 tumors lacking TLS. C. Representative image 
of ADU S-100 treated B16.F10 tumor resected on day 18 showing sting induced non-classical TLS 
composed of CD11c+ DCs and CD3+ T cells surrounding PNAd+ HEV. D. TLS formation 
quantitated using PNAd+ HEV density in PBS or ADU S-100 treated B16.F10 tumors. Data 
representative of three independent experiments. E. ADU S-100-treated vs control B16.F10 
tumors demonstrate marked increase in number of physical contacts between infiltrating CD11c+ 
DCs and CD3+ T cells. *p < 0.05; **p < 0.002; ***p < 0.0002; ****p < 0.0001. Scale 
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bar=100µm. DCs, dendritic cells; TLS, tertiary lymphoid structures; TMS, tumor 
microenvironment; TNF, tumor necrosis factor. 
 
2.4.4 Host cell but not melanoma STING signaling drives the anti-tumor response, VN 
and TLS formation in the TME 
In addition to innate immune cells, B16.F10 melanoma cells intrinsically express STING (data not 
shown) and could theoretically respond directly to ADU S-100. To parse out the role of tumor-intrinsic 
STING activation in the observed therapeutic responses, we administered low-dose ADU S-100 to WT 
or STING KO (Tmem173gt) mice bearing established STING+ B16.F10 melanomas (Fig. 14A). 
Interestingly, despite tumor-intrinsic expression of STING in both models, ADU S-100-based therapy 
failed to effectively treat (Fig. 14B), promote the development of TLS-associated PNAd+ HEVs in the 
TME (Fig. 14C) or promote VN (Fig. 14D) in B16.F10-bearing STING KO mice (vs WT mice). 
In extended studies, we determined that treatment of B16.F10 melanoma cells in vitro with ADU S-
100 failed to promote tumor cell apoptosis (Fig. 14E) or tumor cell production of TLS promoting 
factors or canonical STING pathway gene activation (Fig. 14F). These data emphasize: i.) the selective 
importance of STING activation in host cells for the observed therapeutic effects of ADU S-100 
administered into the TME and ii.) an apparent intrinsic defect in STING signaling in B16.F10 cells in 




Figure 14: Host STING expression is required for therapeutic VN, TLS neogenesis and 
treatment benefit. 
A. Schematic representation of animal experiments performed using WT and sting KO 
(Tmem173gt) mice. Treatment timelines for PBS or ADU S-100 were identical as in previous 
experiments. All mice received S.C. injections of STING+ B16.F10 tumors. (n=5/group) B. Tumor 
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growth curves of WT and sting KO mice showing observed therapeutic effect in only the ADU S-
100 treated WT host group. *p < 0.05, ***p < 0.0002; ****p < 0.0001, two-way ANOVA. C. 
Quantitation of HEVs in WT host or sting KO host receiving ADU S-100 or PBS **p < 0.002, one-
way ANOVA. D. Representative images showing VN as a function of pericyte coverage and VEC 
activation in tumors resected from WT hosts, but not from sting KO hosts, treated with ADU S-
100. *p < 0.05; **p < 0.002, one-way ANOVA. E. Representative flow cytometric plots from 
apoptosis assay on cultured B16.F10 cells confirming sting agonism is not directly tumoricidal. 
F. Quantitative rtPCR validation of the lack of response to sting activation in B16.F10 cells (as 
compared with responsive CD11c+ DCs). ****p < 0.0001, one-way ANOVA. Scale bar=100µm. 
ANOVA, analysis of variance; DC, dendritic cell; i.t, intratumorally; rtPCR, real time PCR; TLS, 
tertiary lymphoid structures; VN, vascular normalization. 
 
2.4.5 Therapeutic STING activation expands a TIL repertoire unique to the TME 
ADU S-100 treated tumors exhibited increased infiltration by CD3+/CD8+ T cells (Fig. 15A). To 
distinguish how therapy impacted the day 18 TIL repertoire, we performed TCRseq analyses of the 
TCRβ-CDR3 repertoires of TILs and animal-matched splenocytes isolated from STING agonist-treated 
vs. control-treated tumor-bearing mice.  
Quantitative TCRseq comparisons demonstrated an increase in the ratio of T cells (i.e. TIL) per 
nucleated cell sequenced within ADU S100-treated tumor samples consistent with our flow cytometry 
data (Fig. 15B). This metric also normalizes quantitative sequencing bias across all samples. We next 
compared productive TCR rearrangements, indicative of the number of distinct T cell clonotypes (as 
an index of population richness) within TIL and observed a significant increase in the number of 
productive TCR rearrangements within the ADU S-100 treated TILs when compared to control TILs 
(Fig. 15C). This suggested that the STING-activated TME supports improved infiltration of divergent 
T cell clonotypes when compared to control tumors. To parse out the source of the therapy-associated 
repertoire observed within ADU S-100 TILs, we compared frequencies of clonotypes in ADU S-100 
treated or control TILs with animal-matched splenocytes (Fig. 15D). We hypothesized that local 
STING activation, by virtue of its induction of VN and TLS formation, would not only increase 
recruitment of clonotypes cross-primed in the periphery (as indexed in spleen), but also initiate de novo 
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expansion of unique clonotypes based on local T cell cross-priming within the TME.  When expanded 
clonotypes (clonal count > 10) were compared between animal-matched spleen and tumor specimens, 
we indeed observed significant increases in TIL clonotypes shared with spleen in ADU S-100 treated 
tumors vs control tumors, supportive of VN-enhanced recruitment of peripherally-expanded T cells 
(Fig. 15E). Further, when compared to control mice, we also observed a significant increase in the 
number of expanded clonotypes unique to the TME (vs. spleen) after treatment with ADU S-100 (Fig. 
15F). These quantitative and compartmental changes in T cell clonotypes in ADU S-100- vs. control-
treated animals resulted in an overall increase in oligoclonality of the therapeutic TIL TCR repertoire 
(Fig. 15G). These data support the notion of independent evolution of the therapeutic T cell repertoire 




Figure 15: Therapeutic STING activation expands a TIL repertoire unique to the TLS+ TME. 
A. Representative flow cytometry plots from day 18 ADU S-100 treated or control tumors 
showing increased infiltration of CD8+ T cells post-STING activation. B. TCRseq analysis 
confirming increased T cell presence in ADU S-100 treated bulk tumor samples sequenced. C. TILs 
in ADU S-100 treated tumors characterized by increased populational richness (greater number of 
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divergent clonotypes/sample). D. differential abundance plots comparing relative frequencies of 
expanded clonotypes (using cut-off clonal count >10) between matched TILs and splenocytes. E. 
ADU S-100 treated tumors (vs control tumors) exhibit expansion in T cell clonotypes common to 
peripheral tissues (ie, spleen). F. ADU S-100 TILs (vs control TILs) contain expanded T cell 
clonotypes unique to the Tme. G. TILs in ADU S-100 treated tumors demonstrate increased 
clonality (more oligoclonal) compared with TILs from PBS-treated tumors. n=5/cohort. TCRseq 




Novel findings presented in our report include the ability of low-dose STING agonist ADU S-100 
to mediate therapeutic inhibition of melanoma growth by coordinately: i.) promoting tumor VN and 
lymphangiogenesis, ii.) stimulating CD11c+ DC maturation and local production of VN- and TLS-
promoting factors, iii.) facilitating enhanced immune cell infiltration and the induction of non-classical 
TLS formation (devoid of organized B cell regions, i.e. germinal centers) in the TME, and iv.) 
enhancing the quantity and richness of the TIL repertoire within the therapeutic TME of TLS+ 
melanomas. The observed in vivo therapeutic benefits associated with ADU S-100 treatment required 
STING expression in host cells and were independent of intrinsic STING signaling in tumor cells. 
Indeed, STING signaling in the B16 and BPR murine tumor cell lines appears dysfunctional 
(Chelvanambi et al., manuscript in preparation), a finding consistent with recent published analyses 
of human colon carcinomas and melanomas322. 
Our data suggest a mechanism in which low-dose STING activation reprograms several aspects of 
the melanoma vasculature to confer immunotherapeutic benefit. First, by increasing local production 
of anti-angiogenic factors, STING activation helps normalize the melanoma vasculature to restore 
tissue normoxia and the functionality of these major conduits for recruitment of circulating immune 
cells. Our findings in melanoma models parallel observations by Yang and colleagues in lung 
carcinoma models for the ability of STING agonists to serve as conditioning agents to promote VN 
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and to synergize with therapeutic checkpoint blockade323. Second, STING activation promotes the 
local production of homeostatic chemokines and LTβR agonists to sponsor the formation of 
HEVs/tertiary lymphoid structures within the TME, where local (cross)priming of naïve/central 
memory T cells may take place. We show that both cultured BMDCs treated with ADU S-100 and 
CD11c+ DCs isolated from the ADU S-100-treated TME exhibit improved maturation and enhanced 
production of factors supportive of TLS/HEV neogenesis, without excluding the possible additional 
contributions of other STING responsive (non-tumor) cell types found within the TME. Future studies 
using scRNAseq are expected to shed light on the selective/relative contributions of other cell types 
(macrophages, VECs, fibroblasts, stromal cells, etc.) for their roles in promoting VN and HEV/TLS 
formation. 
Biophysically, VN and lymphangiogenesis together serve to reduce tumor interstitial fluid pressure, 
permitting improved trans-endothelial diffusion and convection of luminal contents including small 
molecule drugs and immune effectors into the TME175. Together with improved endothelial cell 
activation, STING agonist-treated vessels are expected to actively recruit and shuttle immune effectors 
into the tumor interstitium. Through HEV neogenesis and by virtue of approximating (DC-mediated) 
antigen cross-priming at source sites of antigen load, TLS are expected to improve TIL infiltration and 
local T cell cross-priming, leading to an expanded, diversified anti-tumor T cell repertoire.  
Indeed, through analysis of the TIL TCRβ-CDR3 sequences, we observed an increase in the 
richness, clonality and uniqueness of the TIL repertoire of STING agonist-treated tumors vs control 
tumors, suggesting therapeutic benefits likely result from the participation of both peripherally and 
locally expanded TIL clonotypes. This finding may explain the widely observed improvement in 
efficacy of ICB when combined with STING agonists, wherein pre-conditioning tumors with STING 
activation may facilitate TLS formation and the development of locally expanded and diversified T cell 
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repertoire best adapted to react to antigenically heterogeneous tumor clonotypes160 324-326. Clonotypic 
comparisons of TILs with animal-matched splenic T cells revealed that TILs from ADU S-100 treated 
mice were significantly enriched with, both, peripherally shared clonotypes (primed within SLOs) and 
TME-unique clonotypes which qualitatively support the likely therapeutic relevance of VN and TLS 
neogenesis on-treatment with STING agonists. While our study, and a majority of TLS studies, cannot 
conclusively demonstrate that the detected TME-unique T cell clonotypes were cross-primed within 
therapy-induced TLS, our findings are consistent with other studies linking TLS and local T cell cross-
priming250 327 and the diversification of disease-relevant T cell repertoires via an epitope spreading 
paradigm328. Future studies characterizing the tumor antigen specificity of engineered T cells bearing 
the TME/TLS-restricted CDR3 sequences as found within ADU S-100 treated tumors may provide 
additional support for their therapeutic relevance and contribute to the design of novel adoptive cell 
therapy approaches in the melanoma/cancer setting. 
Recently, B cells have been reported to represent a positive prognostic biomarker in human solid 
cancers by virtue of their production of anti-tumor antibodies and their ability to serve as tumor-resident 
APCs329-333. B cells have also been reported to promote a pro-TLS tissue microenvironment based on 
their robust production of LIGHT/TNFSF14334. However, in our studies, we did not observe significant 
B cell infiltration, germinal center (GC) formation or the development of classical TLS (Fig. 11B). 
Consistent with this finding, neither our GSEA of ADU S-100-treated DCs nor transcriptional analyses 
of tumor specimens identified pathways relevant to B cell recruitment/infiltration or the initiation of 
humoral responses (Fig. 10A, Fig. 11A). Furthermore, we found no evidence for increased local 
production of the B cell homeostatic chemokine CXCL13 post-treatment with ADU S-100 in DCs (Fig. 
9G) or tumors (Fig. 13A). Given these findings, treatment strategies combining STING agonists with 
agents that promote B cell, follicular DC (FDC) and/or TFH recruitment into the TME might lead to the 
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more effective formation of classical mature TLS in the TME, resulting in enhanced treatment benefit. 
Candidate agents that activate TLR7/9 on DCs335 336 or that block DNMT1 (decitabine) in the TME to 
promote enhanced CXCL13 production could be considered for use in such combination protocols337. 
However, one should also carefully consider previous reports linking B cells with tumor progression338-
340,341.  Regardless of the ultimate role for B cells in a therapeutic TLS paradigm, it is noteworthy that 
in humans, the presence of either classical/mature or non-classical (i.e. B-deficient) TLS in the TME 
correlates with improved patient outcome when compared to patients with tumors that fail to exhibit 
TLS320. 
While our studies were not specifically designed to identify mechanisms underlying resistance to 
i.t.-delivered STING agonist-based monotherapy that may have led to modest clinical activity in early-
phase clinical trials, we observed that the treatment of DCs with ADU S-100 resulted in the 
compensatory upregulation of several known regulatory molecules that would be expected to mediate 
anti-inflammatory activity and thereby limit the therapeutic anti-tumor immune response. Notably, we 
observed that PD-L1, Ptgs2/COX2, Ptges and Arg2 expression were strongly upregulated on STING-
activated DCs, suggesting these APCs may not mediate optimal/sustained immunostimulatory activity 
in vivo (Fig. 16)342. Other pre-clinical studies have indeed demonstrated therapeutic synergy when 
combining STING agonists with checkpoint inhibitors324-326 or COX-2 inhibitors305 in vivo, suggesting 
that antagonism of immunoregulatory pathways induced by STING activation might prove crucial for 
successful treatment of multifocal, advanced-stage disease. We are currently investigating the 
therapeutic impact of combined treatment with STING agonists + anti-PD-L1 and/or inhibitors of 
PTGES, PTGS2/COX-2 and ARG2 to determine impact on VN, TLS formation, TIL repertoire and 





Figure 16: STING mediated inflammation concomitantly upregulates expression of immune 
regulatory molecules by CD11c+ DC.  
A. Transcriptional profiling of isolated CD11c+ DC treated with ADU S-100 vs. control media for 
immunoregulatory gene products including Arg2, Nos2, Pdl1, Ptges and Ptgs2/COX-2. Specific 
transcript levels determined by qRT-PCR as in Fig. 3. *p-value < 0.05, unpaired t-test. 
 
Finally, a number of studies, including ours, have highlighted the local therapeutic benefits of 
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but these interventions lead to only modest therapeutic impact on distal, untreated lesions in multifocal 
disease models in which only one tumor is treated (Fig. 17), Furthermore, systemic (i.p.) delivery of 
ADU S-100 fails to effectively treat s.c. B16.F10 tumors in vivo (data not shown). Given these logistic 
limitations for second-generation STING agonists, there is significant enthusiasm for future 
investigation of next-generation small molecule STING agonists designed for systemic delivery that 
have entered evaluation in early-phase clinical trials (i.e. SB11285 and GSK3745417). These agents 
will enable further testing of our proposed therapeutic paradigm in models of multifocal, disseminated 
melanoma treated i.v./i.p. with low doses of STING agonists.  
 
Figure 17: Lack of prolonged systemic response with ADU S-100 in bilateral B16.F10 models. 
B16.F10 tumor growth curves from pilot trials showing lack of extended therapy in un-injected 
























































Antigen Clone Vendor Concentration
CD3 Alexa Fluor 647 17A2 BioLegend 1:50
CD45 Alexa Fluor 488 30-F-11 BioLegend 1:100
CD11c Alexa Fluor 488 N418 BioLegend 1:100
PNAd Purified MECA 79 BD Pharmingen 1:100
CD31 Alexa Fluor 647 MEC 13.3 BioLegend 1:50
B220 FITC RA3-6B2 Pharmingen 1:100
Lyve-1 Purified ALY7 Invitrogen 1:100
PRGFRβ PE APB5 Invitrogen 1:100
VCAM1 Purified AF643 R&D Systems 1:100
Lectin Alexa Fluor 488 DL-1174 Vector Labs 200 μg/mouse
CD133 N/A Santa Cruz Bio 1:100
Jarid1b N/A Abcam 1:500
pIRF3 CST 29047S CST 1:1000




Table 5: List of qPCR primers used 
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3.0 General Discussion 
3.1 Thesis summary 
T-cells are extremely efficient in the surveillance and rejection of transformed cancer cells due 
to their ability to mount specific and potent cytotoxic anti-tumor responses. Given this, improved 
T-cell infiltration into the TME is a strong indicator of functional tumor immunosurveillance in 
situ and desirable clinical outcomes 138 343 344. However, cancers evolve cellular and molecular 
mechanisms (both intrinsic and conferred to stromal cells) to limit interaction with and recognition 
by T-cells, as discussed in detail in the introduction to this thesis. Importantly, T-cell access to the 
tumor relies upon vascular networks which are known to be both structurally and functionally 
abnormal in solid cancers thus implicating the aberrant tumor vasculature as a major culprit for T-
cell exclusion. Therefore, strategies that disrupt pathologic angiogenesis within the TME are 
expected to ‘normalize’ the tumor vasculature to promote T-cell infiltration into immunologically 
cold tumors and several such strategies are also discussed in the introduction to this thesis. In this 
regard, agents that activate STING, an innate immune sensor for cytosolic DNA, have recently 
demonstrated strong angiostatic potential as evidenced by significant vaso-ablation with non-
therapeutic near-MTD dosing. Subsequent dosing studies have instead shown remarkable T-cell 
mediated tumor protection with sub-MTD doses of STING agonists but therapeutic changes to the 
tumor vasculature with such modified dosing regimen have not yet been characterized. Therefore, 
given the strong angiostatic potential of STING activation, we hypothesized that treatment with 
low, sub-MTD doses of STING agonism will lead to ‘normalization’ of the tumor vasculature and 
of the resultant therapeutic immune landscape, leading to sustained local inflammation necessary 
for successful T-cell mediated tumor clearance. 
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Indeed, in this thesis, I have shown that provision of metronomic low doses of STING agonists 
promote anti-tumor responses by significantly improving the TIL footprint within murine 
melanoma lesions. I considered two important observations to design my first hypothesis to 
explain the observed improvement in T-cell infiltration on-treatment.  First, melanomagenesis is 
driven by rapid neoangiogenesis involving the integration of structurally- and functionally 
defective blood vessels. Second, tumor endothelial cells demonstrate a heightened sensitivity to 
STING-associated inflammation, with near-MTD doses of STING agonists ablating endothelial 
cells 269 306 345 found within the TME. Considering that T-cells depend on blood vessels to enter 
the TME, and in light of the therapeutic vascular paradigms proposed by Rakesh Jain and 
colleagues175 176, I hypothesized that poor baseline T-cell infiltration in melanoma can be attributed 
to the dysfunctional vessels and that the functional normalization of these conduits with low-dose 
anti-angiogenic STING agonists will underlie the enhanced T-cell infiltration achieved on-
treatment. In support of this hypothesis, I first observed that intratumoral activation of STING led 
to increased transcript levels of anti-angiogenic factors with no noticeable changes in pro-
angiogenic factors within the TME, suggesting that low-dose STING agonism sponsored a 
generally angiostatic tumor microenvironment. I next probed for structural and functional 
biomarkers of vascular normalization (as proposed by Jain et al.) such as vessel perfusion and 
pericyte coverage of tumor vasculature175 176 and indeed observed that tumor vasculature on-
treatment with ADU S-100, developed vasculature that had, both, significantly improved luminal 
perfusion and enhanced abluminal coverage of endothelial cells by mural pericytes. Further since 
TNFα and type-I IFN were upregulated with STING activated TME, and given their independent 
roles as activators of endothelial cells 346-348, I probed for markers of vessel activation and found a 
significant increase in VCAM-1+ activated endothelia on-treatment. In addition to these functional 
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improvements in the blood vasculature, I also observed an increase in density of Lyve-1+ lymphatic 
vessels on-treatment which further normalizes the TME by draining pooled interstitial plasma to 
relieve high tissue pressure 176. These findings suggest that STING activation results in an overall 
reprogramming and activation of tumor vascular networks. Consistent with occurrence of such 
reprogrammed tumor vasculature on-treatment, I observed a significant reduction in tissue hypoxia 
as evidenced by decreased transcript levels of Hif1α and Hif2α and decreased surface expression 
of hypoxia responsive cancer stem cell markers Jarid1b and CD133 within the ADU S-100 treated 
TME 204. Together, STING agonism normalizes the TME by improving vessel functionality and 
reducing tissue hypoxia which may synergistically improve T-cell infiltration and/or function 
within the TME. 
Interestingly, in addition to improved T-cell infiltration, I also observed a significant increase 
in intratumoral CD11c+ DC in STING activated tumors. Given the contextual ability of CD11c+ 
DCs to skew inflammatory responses 349, I next characterized the transcriptional changes 
associated with STING activated DCs to further investigate the nature of the local immune 
response induced by such STING conditioned tumor infiltrating APCs. Using DNA microarray 
analyses, I found that STING activation in CD11c+ DCs promoted their acute activation and 
maturation as previously reported in the literature. But most remarkably, GSEA performed on the 
transcriptional dataset predicted STING activated DCs to be involved in the formation and 
maintenance of lymphoid tissues. Such ectopic lymphoid aggregates in peripheral tissue sites are 
referred to as tertiary lymphoid structures (TLS) which provide a site for lymphocytes to interact 
with APCs for enhanced local (re)priming 230 240. This suggested that intratumoral STING 
activation, at least in part by conditionally activating infiltrating DCs, could promote the formation 
of TLS within the TME. In line with observing no increase (and possibly a decrease) in the local 
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production of CXCL13 with STING agonism, I postulated that any induced TLS with ADU S-100 
would be of the non-classical type i.e., that they would lack germinal center B-cells. Indeed, 
through histological characterization, I observed non-classical TLS in ADU S-100 treated tumors 
that were characterized by the aggregation of T-cells and DCs, but not B-cells, around PNAd+ 
HEVs within the STING-activated TME. These changes were strictly dependent on the activation 
of host STING since tumor bearing STING KO hosts resembled control WT hosts with regards to 
all therapeutic biomarkers considered (tumor growth, VN and HEV/TLS neogenesis).  
Since STING activation promoted, both, the normalization of existing tumor vasculature and 
induction of lymph node-like vasculature, I proposed that these changes would importantly impart 
a qualitative difference to the TIL repertoire in addition to the previously observed quantitative 
differences. Based on this working understanding, I next hypothesized that the TIL repertoire on-
treatment with ADU S-100 would be characterized by 1) An improved infiltration of peripherally 
shared clonotypes as a result of normalizing tumor vasculature 2) An enhanced expansion of a 
TME unique repertoire as a result of promoting local priming via HEV/TLS neogenesis. To test 
this hypothesis, I profiled the clonotypic identities (qualitative) and associated quantities of each 
TIL clonotype with regards to its distribution in the periphery (indexed in spleen) by sequencing 
TCRβ-CDR3 identities in each sample. The data from these sequencing assays supported my 
hypothesis by demonstrating, both, quantitative and qualitative differences in TIL repertoires. 
Briefly, I observed 1) a significant increase in the number of expanded TIL clonotypes that were 
also indexed in animal matched, paired spleens suggesting that therapy with STING agonists 
promoted enhanced infiltration of T-cells from the circulation 2) a significant increase in the 
number of expanded TIL clonotypes that were unique to the TME suggesting an independent 
evolution of a TIL repertoire unique to the STING activated TME. Associated with these 
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quantitative and qualitative differences, STING activated TIL repertoires demonstrated increased 
population richness and increased oligoclonality suggesting that therapy with ADU S-100 was 
associated with the participation, local expansion and independent evolution of divergent T-cell 
clonotypes in the TLS+ TME. 
Overall, the work presented in my thesis proposes that therapeutic T-cell responses observed 
with low-dose STING agonism in melanoma can be attributed to fundamental changes to the 
existing tumor vasculature as well as induction of a specialized lymph node-like neovasculature 
(HEVs). This creates an actionable TME for the enhanced infiltration and local function of immune 
cells; especially CD8+ T-cells. Further, local activation of host cells, including but not limited to 
CD11c+ DCs, changes the local inflammatory landscape to support the formation of non-classical, 
B-cell devoid, TLS within the TME where newly infiltrating T-cells may encounter novel 
epitopes/antigens presented by tumor associated APCs. These observations crucially offer novel 
insights for STING-based therapeutic regimen by highlighting the therapeutic involvement of 
reprogrammed vasculature that sponsor the function of both, peripherally- and locally expanded 
clonotypes within the STING-activated TLS+ melanoma TME (summarized in Appendix fig. 1). 
3.2 B-cells and germinal centers in TLS 
While we did not expect nor observe significant changes in B-cell infiltrates in our model, 
recent evidence suggests B-cells, especially when organized in germinal centers within TLS, might 
be beneficial for the control of tumor progression. In a hallmark study, Helmink et al. demonstrated 
that B-cell signatures correlated positively with clinical outcome in metastatic melanoma and 
colorectal carcinoma patients receiving ipilimumab and nivolumab combination treatments. In 
these patients, histological examination of tumor biopsies showed B-cell aggregates that closely 
resembled the germinal centers found in SLOs 232. B-cells in these tumor-resident germinal center 
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(GC) demonstrated an increased clonal expansion, increased total BCR diversity, enhanced 
proliferation (as a function of Ki67 expression) and evidence of class switching from IgM 
expressing naïve B-cells to IgG expressing class-switched B-cells when compared to non-GC B-
cells found within the TME 232. T-cells in TLS+ melanoma patients also benefitted from associating 
with GC B-cells as was evidenced by the elevated signatures of T-cell activation markers CD44, 
GZMB and 4-1BB when compared to disperse T-cell infiltrates found outside of GC B-cell zones 
232. This suggests that B-cells within TLS retain an active role in the ongoing anti-tumor response 
but the extent of their involvement i.e., through direct ‘helper-like’ cellular responses or through 
indirect systemic humoral responses, is yet to be characterized. In most solid cancers, attributing 
tumor reactivity and specificity of such TLS B-cells is made complicated by the challenges in 
associating BCR identities to the three-dimensional, non-contiguous epitopes that B-cells typically 
recognize on tumor antigens. 
However, the unique epidemiology of head and neck squamous cell carcinoma (HNSCC) 
provides an excellent model to study the functional role of antigen specific TLS B-cells since the 
human papilloma virus (HPV) serves as an etiological agent for a small cohort of HNSCC patients. 
Besides inducing an inflammatory TME for the neogenesis of TLS, HPV driven cancers contain 
viral antigens, whose identities are better characterized, against which anti-tumoral B-cell and T-
cell responses can be monitored. Indeed, TLS with GC B-cells are found more frequently in HPV+ 
HNSCC patients than in HPV- HNSCC patients 234 350. In HPV+ patients, GC+ TLS correlate with 
better clinical prognoses and B-cells found within the TLS differentiate to produce large quantities 
of antibody (hence called antibody secreting cells or ASCs)234, which suggests that antibody 
promoting responses within the TME could be a harbinger of good clinical response351. In 
extension of these findings, antibodies sequenced from TLS+ patients showed evidence of having 
91 
 
undergone extensive somatic hypermutation352 and class switching from IgM/IgD to IgG1 and 
IgG2/3 234 and demonstrated an enhanced ability to recognize non-structural HPV proteins E2, E6 
and E7. Together, these observations suggest that B-cell priming against HPV antigens within the 
TME (presumably within such classical TLS) leads to the development of a protective systemic 
humoral response234. It is therefore within reason to expect the TLS generated humoral responses 
to confer systemic immunity through neutralization of pro-tumoral proteins, induction of 
phagocytosis353 354, ADCC 355 356 and complement formation 357-360 to support tumor clearance. 
Intriguingly, TLS B-cells selectively produce IgG1 antibodies which capably induces type-1 
inflammatory responses via the activation of FcGR1A on NK cells and macrophages for ADCC 
and phagocytosis respectively 361-363. In addition, B-cells found within such TLS could also serve 
as APCs to effector T-cells, provide antigen-independent help with T-cell activation 364 and/or 
promote local DC functionality through enhanced expression of CD40L 365-367. Collectively, these 
studies present compelling evidence in favor of promoting the recruitment of B-cells to the TME 
to improve current cancer therapies.  
Although the above instances highlight the role of GC B-cell aggregates and classical (mature) 
TLS in cancer, non-classical (immature) forms of TLS characterized by different participating 
immune cell types have been observed in cancer 244 368-370 where such B-cell devoid TLS, 
quantified by PNAd+ HEV density and/or TLS associated cytokine signatures238 239, also correlate 
with better clinical outcomes. Consistent with the putative functional role of either type of TLS, 
my work demonstrates the development of a unique TIL repertoire within the TLS+ ADU S-100 
treated TME which was not evidenced in the periphery. We would thus propose that combination 
regimens, like with the inclusion of TLR7 agonists 335 336 371, that promote the local expression of 
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CXCL13 may be required to achieve classical B-cell+ TLS formation in therapeutic regimens using 
STING agonists. 
3.3 Lack of systemic clinical benefit with local STING agonism 
While STING activation significantly improved local therapeutic responses in the injected 
lesion, an important question for locally delivered drugs, such as ADU S-100, in metastatic disease 
lies in whether therapy confers systemic protection against metastatic growth or in the setting of 
multi-focal disease. This is particularly important for clinical feasibility and translatability since 
distal lesions are often found in inaccessible sites, such as the brain and lungs. To address if 
intratumoral ADU S-100 injections conferred systemic protection, we performed pilot studies on 
mice harboring established B16 melanomas, treating only the right flank tumor with i.t. PBS or 
ADU S-100 (5 μg/tumor on days 10 and 14). Although the contralateral un-injected tumors in 
ADU S-100 treated animals grew at a slightly slower rate vs. PBS control-treated mice up to day 
13 (p=0.06), these tumors eventually progressed after treatment discontinuation on day 14 and 
paralleled the growth of control PBS tumors on both flanks (Fig. 17). This suggests that although 
early immune responses arising from intratumoral STING activation results in slowed tumor 
growth of distal lesions, the prolonged efficacy of the anti-tumoral immune response appears to be 
limited. It may be possible that innate immune activation of NK cells and macrophages may be 
responsible for this acute control. However, we believe such promising early responses may be 
further extended temporally and/or accentuated via combination immunotherapy approaches 
integrating local or systemic STING agonists, checkpoint blockade to reinvigorate activated T-
cells and/or other immune-potentiating agents that are upregulated in response to STING 
activation. Interestingly, since other groups have demonstrated efficacious control of bilateral 
tumors of breast and colon cancer origins with single lesion intratumoral injection of ADU S-100, 
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it may be possible that interlesional heterogeneity in melanoma might represent a significantly 
greater hurdle than that observed in other tumors. One may speculate that inherent properties of 
melanomagenesis, including aggressive growth, loss of PTEN and/or dysfunctional angiogenesis, 
could be candidate causative factors but further validation with systemic STING agonists are 
necessary to address these challenges.  
3.4 Intrinsic STING signaling defects in melanoma cells 
 Comparison of the tumor growth kinetics in STING KO and WT hosts receiving ADU S-100 
conclusively demonstrated that STING activation in the host was sufficient and necessary for the 
anti-tumor responses observed with ADU S-100 (Fig. 14B). Contrastingly, this also suggested that 
B16.F10 tumors might be refractory to STING activation since STING KO hosts receiving ADU 
S-100 completely failed to develop a therapeutic response. Based on follow-up pilot data and 
findings already presented in the published literature, we propose that tumor intrinsic STING 
signaling defects might be caused by one or more of the following reasons. 
3.4.1 STING or TBK1 degradation 
 Studies analyzing anti-viral responses highlight several pathways that regulate STING protein 
expression to limit the development of irAEs. These maybe extended to the tumor setting as 
possible axes of resistance. First, P62/SQSTM1 is a protein involved in the STING signaling 
cascade that is also phosphorylated by TBK1 but serves to chaperone ubiquitinated STING to the 
autophagosome for degradation372. Accordingly, stimulation of P62 deficient cells with 
extracellular DNA shows defective shuttling of STING into autophagosomes resulting in chronic 
STING signaling and an associated increase in IFN-I secretion in vitro372. Considering this 
evidence, gain of function mutations in tumor associated P62 could be one causative factor for 
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poor STING response in melanoma. Second, STING signaling in melanoma may be attenuated 
downstream of STING and at the level of TBK1 through the increased expression of proteins 
implicated in TBK1 degradation such as SOCS3 373-375, DDX19376 and TRAF3IP3377. Of these 
proteins, SOCS3378 379 and TRAF3IP3380 have been previously found to be highly expressed in 
melanoma and may be responsible for STING dysfunction. If true, these proteins factor as novel 
targets for therapeutic intervention to reconstitute tumor intrinsic STING signals. 
3.4.2 Defects in IRF3 phosphorylation 
 While comparing B16.F10 melanoma cells to syngeneic bone marrow-derived dendritic cells 
(DC), we found that although both cell types express sufficient levels of STING, TBK1 and IRF3 
proteins, only DCs stimulated with ADU S-100 were competent to induce the 
activation/phosphorylation of IRF3, suggesting that melanoma cells exhibit a signaling defect 
downstream of STING but upstream of IRF3 activation (Appendix fig. 2). Signaling downstream 
of STING could theoretically be silenced by i.) structural mutations in STING that preclude its 
effectiveness in serving as a scaffold for TBK1-IRF3 interaction necessary for the phosphorylation 
of IRF3288 or ii.) overexpression of inactivating protein tyrosine phosphatases (PTPs), such as 
PTPN1/PTP1B, PTPN2, PTPN11/SHP2, Cdc25A, MAPK phosphatase 5/DUSP10, each of which 
has been reported to interact with STING, TBK1 and/or IRF3381-385  
3.4.3 Defects in transportation and degradation of DNA/CDN 
  It is also entirely possible that events independent of and unrelated to the STING signaling 
cascade could dictate tumor STING dysfunction. Two potential hypotheses to test this idea 
include: i) melanoma cells contain/acquire loss of function defects at the level of DNA/CDN 
membrane transporters necessary for adequate cellular uptake of STING agonists and ii) 
melanomagenesis is associated with gain of function mutations at the level of proteins involved in 
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the intracellular degradation of DNA. Firstly, previous reports have suggested that aggressive 
melanoma growth is accompanied by a change in surface expression of membrane transporters 
that support tumor progression386. While it was clear that extracellular CDNs possessed the ability 
to be taken up by cells, the exact identity of the membrane transporter responsible for their uptake 
remained largely unknown. In a recently published study using CRISPR knockdown libraries, 
SLC19A1 was identified as the transporter that is primarily responsible for the intracellular uptake 
of both, cGAMP and CDNs387. SLC19A1 deficient THP-1 monocytic cells with intact STING, 
TBK1 and IRF3 lose all downstream signaling and IFN-I production in response to extracellularly 
administered CDNs387. Considering this, it would be of interest to evaluate the expression and/or 
functional status of SLC19A1 in melanoma to address if functional defects with transporting CDNs 
is a causative factor for STING dysfunction. Alternatively, connexons play important roles in 
transporting cGAMP/CDNs between cells via the gap junctions they polymerize to form 388. If 
mutations/functional changes in these proteins are indeed the drivers of STING dysfunction in 
melanoma, targeted genetic correction/rescue can be proposed to coerce melanoma cells to respond 
to STING agonists to ultimately improve the efficacy of STING agonists for the clinical control 
of cancer.  
 Second, exonucleases are responsible for the timely degradation of genetic material in order to 
avoid overactivation of DNA repair and DNA sensing pathways 389. Overexpression of DNA 
exonucleases could lead to a reduced half-life of second messengers cGAMP and CDNs thus 
placing temporal restraints on events preceding STING activation. In this sense, Trex1 is one such 
exonuclease that is overexpressed in melanoma390 and therefore represents one of many possible 
candidates to be tested through this hypothesis. While it is unclear if CDNs, like dsDNA, are 
susceptible to the catabolic activity of exonucleases, it would be of great scientific/therapeutic 
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interest to determine if Trex1 overexpression in melanoma correlates with STING dysfunction 
and/or failed clinical response.  
3.4.4 Epigenetic silencing of STING responsive elements 
 A final possibility lies at the level of epigenetic modifications at IRF3/7-responsive promoter 
regions. In human colorectal carcinoma, dysfunction in intrinsic STING signaling was observed 
to mainly involve the suppression of STING expression via epigenetic regulation, with mutation 
or deletion events in these genes only rarely observed 322 391. Although STING transcripts have 
been reported to be reduced in ~50% of human melanoma cell lines tested 392 as in the case of our 
report, Mulé and colleagues 393 determined that ADU S-100 can fail to activate STING+ human 
melanoma cell lines via an as yet unknown mechanism. However, using a general DNA 
demethylation approach by treating mice harboring B16.F10 tumors with ADU S-100 and a 
DNMT1 inhibitor, Decitabine, we observed a slightly synergistic reduction in the growth rates of 
the tumor in pilot studies (Appendix fig. 3). In vitro profiling of B16.F10 cancer cells showed 
elevated expression of IFN-I and CXCL10 in ADU S-100 + Decitabine treated cancer cells 
suggesting B16.F10 cells broadly possess epigenetic roadblocks downstream of the STING 
signaling cascade (Appendix fig. 3). Regardless, epigenetic modifications possibly represent only 
one part of the bigger challenge with activating STING in melanoma since ADU S-100 + 
Decitabine treated melanoma cells still fail to upregulate several STING associated cytokines such 
as lymphotoxin alpha.  
 While the data presented in this thesis has analyzed this phenotype in detail for B16.F10 
melanoma, the primary tumor model used in my dissertation research, scope-expanding pilot 
studies have observed a similar STING signaling defect in 2 unrelated BRAFV600EPTEN-/- 
melanoma cell lines (BPR, YUMM3.3) after treatment with ADU S-100 in vitro, suggesting 
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STING dysfunction may represent a general paradigm amongst murine melanomas. Current 
research in our lab is investigating each of these possibilities in our 3 murine melanoma cell lines 
including the functional assessment of specific gene knock-down/overexpression and/or 
pharmacologic inhibition experiments and plan to develop and publish our mature results in a 
future report.  
 Regardless, the confounding nature of STING biology in host cells vs tumors does not diminish 
the therapeutic value of ADU S-100/STING agonism since these treatments still sufficiently 
promote VN and HEV/TLS formation in a manner that does not require the involvement of 
melanoma STING. In these circumstances, clearly STING expression in host tumor-associated 
stromal cells appears to be responsible for the therapeutic alterations observed in the melanoma 
TME. At present, we cannot implicate specific host cell subpopulations which would require 
development and implementation of targeted STING-KO mouse models and/or scRNAseq 




4.0 Future Perspectives 
4.1 Future of STING agonists 
STING agonists have become attractive agents for the treatment of cancer, yet the modest 
success or intratumoral delivery approaches in the clinic has energized efforts to develop 
improvements in targeted drug design for enhanced tolerability and efficacy in the disseminated 
disease setting 394. Successful development of the first-generation STING agonist DMXAA 
enabled pre-clinical studies designed to test the role of STING activation as a paradigm for 
effective anti-tumor therapy 304. Intriguingly DMXAA demonstrated only modest efficacy in 
human studies due to its inability to bind human STING variants which possess a different 
conformation than murine STING 281 282 395. Further, DMXAA and natural second messenger 
cGAMP show poor bioavailability given their increased susceptibility to the phosphodiesterases 
found in the circulating blood thus limiting their systemic distribution396-398. ADU S-100, a CDN 
derivative used in all the studies presented in this thesis, addresses these shortcomings by robustly 
binding both human and murine STING and demonstrating a significantly prolonged half-life in 
systemic circulation 303. However, results from early clinical trials suggest that although these 
improvements are sufficient to induce moderate responses in patients, ADU S-100 remains limited 
to approaches involving local delivery via direct intratumoral injection (NCT03937141) and other 
second-generation STING agonists such as E7766 share a similar fate of being restricted to local 
delivery applications (NCT04144140).  These delivery restrictions have also limited use of ADU 
S-100 and E7766 to trials enrolling patients with at least one treatable cutaneous lesion which 
excludes a variety of solid cancers where primary lesions are often surgically inaccessible. Novel 
STING agonists such as Spring Bank Pharmaceuticals’ SB11285 and Glaxo Smith Kline’s 
GSK3745417 have demonstrated improved stability in circulation in pre-clinical models where 
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intratumoral, intraperitoneal and/or intravenous injections confer protective immune responses 
against multiple transplantable models of solid cancer. Successful early phase clinical trials using 
these systemic STING agonists would significantly improve adoptability of STING agonism in 
stand-alone or combination immunotherapy trials. Ultimately, these agents will enhance the testing 
of the proposed therapeutic paradigms discussed in this thesis especially as they pertain to 
multifocal/metastatic disease.  
4.2 Targetable immunoregulatory pathways with STING activation 
Through our GSEA, we observed the upregulation of several compensatory immunoregulatory 
molecules including COX2, PDL1, IDO, ARG2 and PTGES with STING activation and propose 
that the targeted inhibition of these axes using commercially available inhibitors in subsequent 
studies would further enhance the therapeutic response currently observed with single agent 
STING activation 399. Indeed, several groups are investigating the use and efficacy of such 
combination regimen in improving therapy.  
4.2.1 Combination targets in trials  
4.2.1.1 PD-L1 
Combining ICB antibodies with STING activation has emerged as an attractive combination 
strategy especially due to the significant increase in TIL population that is achieved on-treatment 
399. In an ID8-Trp53-/- model of murine ovarian cancer, Ghaffari et al. observed that therapy with 
STING activation was associated with a significant increase in intratumoral infiltration of PD-1+ 
CD8+ T-cells and systemic increase in PD-L1 expressing myeloid MDSC and macrophages 400 
where PD-1/PD-L1 expression may be driven by i) the enhanced production of IFNγ by activated 
TILs, STING and type-I IFN responsive DCs/macrophages/NK cells on-treatment 400 or ii) type-I 
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IFN associated activation of JAK/STAT pathways 120. Indeed, combination of STING agonism 
with ICB in a prostate cancer model showed synergistic efficacy in controlling tumor growth when 
compared to either single treatment modality 324. Encouraging results from such pre-clinical 
combination efforts has led to the inclusion of STING agonists in ICB based clinical trials such as 
those highlighted in Table 3. 
4.2.1.2 COX2  
Separately, we also found that bone marrow DCs upregulated Ptgs2/Cycloxygenase-2 or COX2 
in response to STING activation. COX2 contributes to local immunosuppression through the 
catabolic reduction of arachidonic acid into PGH2; the pro-form of the active immunosuppressant 
PGE2 401. Consistent with our observation of enhanced COX2 production with STING activation, 
a recent report by Lemos et al. found that CDA administration to murine LLC tumors resulted in 
the concomitant upregulation of COX2 in the LLC TME 305. Since murine LLCs eventually relapse 
despite receiving continued administration of STING agonists, the authors hypothesized that 
targeted inhibition of the key immunosuppressive axis coordinated by COX2 would improve 
STING-based therapy by extending survival and preventing tumor relapse. Indeed, the combined 
administration of Celecoxib, a selective COX2 inhibitor, with CDA significantly reduced tumor 
growth rates, prevented relapse and extended survival when compared to CDA monotherapy 305. 
Findings from our studies and from Lemos et al. suggest that COX2 inhibition holds significant 
promise as a co-therapy in future combination STING-based interventional regimens.  
4.2.1.3 IDO 
In a separate study by Lemos et al. the authors observed that relapse with STING activation in 
LLC was accompanied by an enhanced infiltration of immunosuppressive MDSCs402. Analysis of 
the differential gene expression profiles of STING activated tumors from WT mice with their 
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counterparts from STING KO mice revealed that indoleamine 2,3-dioxygenase (IDO) was 
significantly overexpressed in the recurrent tumors from WT hosts 402. Extending this observation, 
they observed that therapeutic administration of IDO inhibitors significantly delayed tumor growth 
in WT hosts receiving STING agonists suggesting that IDO production actively limits therapeutic 
efficacy of STING agonism. Mechanistically, since IDO enzymatically converts tryptophan to 
kynurenine 403, upregulation of IDO within the TME can be expected to deplete local tryptophan 
thereby inducing metabolic dysfunction of tumor infiltrating T-cells 404. Further, an enhanced local 
generation of kynurenine limits anti-tumor immune responses by promoting Treg induction 405 and 
skewing DC differentiation towards more tolerogenic phenotypes 406 suggesting that IDO 
inhibition could also factor as an important combination strategy integrating STING agonist-based 
treatments in the future. 
4.2.2 Novel immunoregulatory targets:  
While PD1/PDL1, COX2 and IDO inhibitors are already being evaluated in combination with 
STING agonists, our analyses highlight Arg2 and Ptges as two additional STING associated 
immunoregulatory molecules whose inhibition via commercially available inhibitors may improve 
current therapeutic responses with STING agonism.  
4.2.2.1 ARG2  
Although the therapeutic anti-tumor role of DCs and T-cells with STING agonism has been the 
focal point of the work presented in this thesis, several other studies have suggested that 
macrophages are also heavily involved in STING based anti-tumor responses. In a recent report, 
Ohkuri et al. demonstrated that therapy with intratumoral injections of cGAMP in CT26 colon 
carcinoma, B16 melanoma and 4T1 breast cancer is associated with an increased infiltration of 
inflammatory macrophages 407. Tumor infiltrating macrophages exhibit a significant degree of 
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phenotypic plasticity and the phenotypic polarization and/or maintenance of a pro-inflammatory 
M1 phenotype or an anti-inflammatory M2 phenotype is largely dependent on the tissue cytokine 
milieu 408. In this context, a significant body of evidence suggests that Arg2 skews macrophages 
to acquire more M2-like phenotypes 409 410. GSEA data from DCs treated with ADU S-100 suggest 
that STING activation indeed upregulates Arg2 production. While we currently have not profiled 
the tumor infiltrating macrophages in our therapeutic model, our data suggests that anti-tumor 
responses with STING agonists could be directly or indirectly dampened via secondary 
promotion/accumulation of M2-like macrophages within the TME. Therefore, the data presented 
in this thesis would recommend the novel inclusion of Arg2 inhibitors with STING-based 
treatments to further enhance therapeutic responses by reinforcing the promotion of M1 
macrophages which independently correlate positively with TLS formation/presence in human 
colorectal cancers 262. 
4.2.2.2 PTGES  
Furthermore, we observed that STING-activated DCs, in addition to upregulating their 
expression of COX2, also upregulate their expression of PTGES/mPGES1, an enzyme responsible 
for the final conversion of PGH2 to bioactive PGE2. By binding to its ubiquitous cognate receptor 
EP4, PGE2 suppresses local inflammation and promotes cancer progression through a variety of 
mechanisms 401. In T-cells, PGE2 downregulates the production of IL-2 and the IL-2 receptor thus 
theoretically weakening Th1 polarization, T-cell activation and T-cell proliferation within the 
STING-activated TME 411. Activation of EP4 receptors on monocytes and DCs by PGE2 results 
in the upregulation of IL-12p40, a competitive inhibitor of the IL-12 receptor 411, and the 
downregulation of key TLS-associated lymphocyte recruiting chemokine CCL19 412 which can 
further significantly: i.) affect nodal priming of naïve T-cells by APCs,  ii.) limit formation of TLS 
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within the STING activated TME. Moreover, PGE2 can dampen the STING-based anti-tumor 
immune response by downregulating the expression of common gamma chain receptors on 
cytotoxic NK cells 413 and promoting tumor-associated macrophage polarization towards the M2 
subtype 414. PGE2 may also contribute to tumor progression via transactivation of PI3K/Akt 415, 
Wnt 415, MAPK 416 pathways. Considering the multi-functional, pro-tumoral role of PGE2, our 
data suggests that, in addition to COX2 inhibition, PTGES inhibition/blockade (such as using 
Cay10526 or Cay10678) should also be tested in combination with STING agonists in future 
investigations. 
4.3 Oncolytic viruses at the confluence of STING activation and TLS neogenesis 
The work detailed in this thesis also extends interesting and novel therapeutic 
outcomes/readouts for other forms of immunotherapy that may introduce foreign/self dsDNA into 
the TME. Oncolytic viruses provide an exciting platform to treat cancers due to i) their specific 
targeted lytic activity in tumor cells and ii) their ability to carry additional therapeutic payloads as 
viral vectors 417. Several oncolytic products are now in trials and include vaccinia based oncolytic 
product, Pexa-vec, and herpes simplex based oncolytic products, T-vec and IMLYGIC418-420. Due 
to their dsDNA genome, it is reasonable to expect these oncolytic viruses to activate STING during 
the course of infection418. Recent literature suggests that oncolytic viruses indeed require and 
activate host STING to mount successful anti-tumor immune responses 391. Interestingly, as was 
the case for my studies using ADU S-100, tumor-intrinsic STING activation does not appear 
central to the success of oncolytic viruses and in fact, may limit oncolytic activity by preventing 
successful and repeated oncolytic infection and inducing immunosuppressive axes 421. Indeed, 
colorectal cancers that harbor loss-of-function mutations in cGAS and STING demonstrate the 
greatest degree of susceptibility to oncolytic viruses (with dsDNA backbones)391. Thus, tumors 
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with silenced/mutated STING might serve as compelling candidates for oncolytic virus-based 
intervention and in this setting, host STING-mediated response to oncolytic viruses might be 
orchestrated by the reprogramming/normalization of the tumor vasculature and local TLS 
neogenesis in the TME as outlined by studies presented in this thesis and by the work of other 
groups studying TLS-induced immune reactions in non-oncolytic HPV+ human cancers234 350. 
Given the growing body of evidence demonstrating an independent ability of several inflammatory 
factors to induce TLS, it may also be proposed that oncolytic viruses can, in addition to activating 
STING, be engineered to induce secretion of cytokines/homeostatic chemokines to further 
potentiate TLS neogenesis within the infected TME. In this light, preliminary studies are underway 
in our group to evaluate the therapeutic and TLS inducing potential of a recombinant oncolytic 
vaccinia virus designed to produce high local levels of TNFSF14/LIGHT, CCL19 and CCL21 






Appendix figure 1: Summary of work presented in this thesis 
The activation of host STING leads to the normalization of existing tumor vasculature and 
HEV/TLS neogenesis where such therapy-associated vascular networks enhance local T-cell 
infiltration associated with slowed tumor growth and extended survival. This enhanced TIL 
footprint in STING activated tumors is qualitatively characterized by both, enhanced quantities 
of peripherally primed T-cells (function of VN) and the existence of a unique repertoire of T-cells 






Appendix figure 2: Tumor-intrinsic dysfunction in STING signaling despite normal expression 
of key pathway components  
A. Immunoblotting confirms expression of STING in CD11c+ DCs and B16.F10 melanoma cells. 
B. Immunoblotting confirms equivalent expression of STING cascade proteins TBK1 and IRF3 but 
activation (phosphorylation) of IRF3 in DCs but not B16.F10 melanoma. Cell lysates for western 
blotting experiments obtained 60 minutes post-stimulation with ADU S-100. 
 
 
Appendix figure 3: DNMT1 inhibition synergizes with STING activation for therapy 
A. Mice harboring s.c. B16.F10 melanoma show synergistic tumor growth control when 
intratumoral ADU S-100 treatments were combined with daily intraperitoneal administration of 
DNMT1 inhibitor Decitabine (DAC). B. In vitro, B16.F10 melanoma cells show enhanced 
production of inflammatory cytokines when tumor cells are pre-treated with DAC prior to STING 
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